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Sintesi 
 
Il termine pseudoartrosi è riferito a un tipo di frattura caratterizzata dall’impossibilità di una 
fisiologica guarigione. Le pseudoartrosi sono tra le complicazioni ortopediche più complesse non 
solo a livello clinico, ma anche a livello socio-economico incidendo drasticamente sia sulla qualità 
di vita dei pazienti colpiti, sia sulle casse dei Sistema Sanitario Nazionale.  
Si stima che il 5-10% dei casi di frattura vada incontro allo sviluppo di pseudoartrosi e generalmente 
le ossa maggiormente interessate a questo fenomeno sono le ossa lunghe, tra le quali tibia, femore, 
omero, radio e ulna. Lo sviluppo di pseudoartrosi può conseguire la perdita di sostanza ossea, ad 
esempio a seguito di traumi o alla resezione di tumori, ma non solo, può anche derivare da una 
frattura che non riesce a consolidarsi. I fattori che possono maggiormente influenzare la corretta 
guarigione del tessuto osseo sono molteplici e spesso correlati allo stato di salute del paziente: la 
presenza di malattie metaboliche, l’età, le abitudini alimentare e il fumo incidono drasticamente sul 
processo di guarigione della frattura. Un’ulteriore causa dello sviluppo di pseudoartrosi è 
l’insorgere di infezioni date da contaminazioni che possono susseguire fratture esposte o che 
possono avere luogo in sede operatoria. In questi casi si parla di pseudoartrosi settiche.  
È stato stimato che circa i due terzi dei casi clinici di pseudoartrosi settiche sono dovuti alla presenza 
di stafilococchi e più specificatamente alla presenza di Staphylococcus aureus and Staphylococcus 
epidermidis. In particolare, S. epidermidis è stato recentemente riconosciuto come un importante 
patogeno opportunista coinvolto nell’aumento di infezioni nosocomiali, essendo comunemente 
presente sulla cute umana. S. epidermidis è un microrganismo commensale presenta 
fisiologicamente nella flora di pelle e mucose. A causa della sua presenza ubiquitaria è spesso 
difficile distinguere se un isolato clinico di S. epidermidis rappresenta l’agente causale di 
un’infezione o un contaminante non specifico della coltura. A differenza di S. aureus, S. 
epidermidis non esprime molteplici fattori di virulenza; è contraddistinto come patogeno dalla 
abilità di formare biofilm sulla superficie di impianti o device introdotti all’interno del nostro corpo 
(ad esempio protesi, pacemakers, cateteri ecc.). 
Il biofilm è una spessa matrice extracellulare secreta da batteri sessili irreversibilmente attaccati ad 
un substrato. All’interno del biofilm i microrganismi creano comunità organizzate in cui, a seconda 
delle influenze ambientali, la comunicazione tra cellula e cellula regola l’espressione di geni 
coinvolti in meccanismi di sopravvivenza. Pertanto il biofilm costituisce una nicchia protettiva, un 
luogo in cui proliferare e sfuggire alle difese immunitarie dell’ospite e ai trattamenti antibiotici, 
portando allo sviluppo di antibiotico resistenze.  
Un mezzo fondamentale e necessario per lo studio della patogenesi delle pseudoartrosi settiche sono 
i modelli preclinici, grazie ai quali è possibile indagare come i batteri interagiscano con l’impianto 
e formino biofilm su di esso. In letteratura, ad oggi, non sono presenti modelli di pseudoartrosi 
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settica causata da S. epidermidis e pertanto nella prima fase del progetto di dottorato è stato quindi 
generato un modello di pseudoartrosi settica in grado di mimare un’infezione nosocomiale 
caratterizzata dalla presenza di un impianto metallico, al fine ultimo di indagare nuove strategie 
preventive e terapeutiche. Con l’obiettivo di identificare la carica batterica minima in grado di 
portare allo sviluppo di pseudoartrosi settiche, i ratti sono stati sottoposti a una frattura femorale in 
cui, a seconda del gruppo sperimentale, sono state inoculate diverse concentrazioni di S. 
epidermidis meticillino-resistente (MRSE). Grazie a questo modello siamo stati in grado di definire 
tre differenti modelli preclinici. È stato infatti possibile dimostrare come un basso inoculo batterico 
(103 CFU/inoculo) è in grado di determinare un modello subclinico di pseudoartrosi settica, 
caratterizzata dalla sporadica presenza di pochi segni clinici di infezione. Abbiamo inoltre descritto 
come un inoculo intermedio (105 CFU/inoculo) sia in grado di determinare segni acuti di infezione 
e come un inoculo alto (108 CFU/inoculo) sia capace di portare ad una rapida formazione di biofilm 
sull’impianto e quindi allo sviluppo di pseudoartrosi in tutti gli animali trattati. I successi ottenuti 
in questa prima fase del progetto hanno reso possibile la realizzazione della successiva fase 
sperimentale in cui, grazie al modello di infezione acuta, abbiamo potuto testare l’efficacia di nuove 
strategie preventive.  
In letteratura sono descritti diversi approcci terapeutici per il trattamento di pseudoartrosi settiche 
e tante nuove ricerche stanno cercando di ottimizzare un trattamento che ancora ad oggi non è 
presente. L’ingegneria tissutale, ad esempio, da anni studia l’utilizzo di scaffold biologici o sintetici 
con proprietà osteoinduttive e antibatteriche per scagionare l’instaurazione di infezioni favorendo 
allo stesso momento la rigenerazione del tessuto osseo. Tuttavia la maggior parte delle proposte 
sviluppate possiede delle limitazioni, legate, ad esempio, alla non biodegradabilità del materiale 
che potrebbe in alcuni casi addirittura favorire l’adesione batterica o legate al tipo sostanze 
antibiotiche caricabili nel materiale. In questo senso gli hydrogel rappresentano un giusto 
compromesso, poiché in grado di fornire localmente antibiotici, fattori di crescita o cellule, 
sfavorendo lo sviluppo di infezioni batteriche associate a impianti.  
È stato recentemente sviluppato un nuovo hydrogel a base di acido ialuronico e polilattico. Test in 
vitro e in vivo di questo rivestimento riassorbibile hanno dimostrato come esso sia in grado di 
prevenire la formazione di infezioni quando associato alla presenza di antibatterico. Tuttavia, non 
sono ancora note le proprietà osteoinduttive/osteoconduttive che si presume abbia questo 
innovativo hydrogel.  
Altri importanti traguardi dell’ingegneria tissutale sono stati raggiunti grazie all’utilizzo di terapie 
cellulari, dove il trapianto di cellule progenitrice ha portato a impressionanti risultati nella 
rigenerazione di organi e tessuti, nonché nel trattamento di pseudoartrosi. Questo approccio mira a 
fornire cellule progenitrici sane in grado di produrre nuova matrice extracellulare all’interno del 
tessuto danneggiato per ripristinare la perdita di funzione del tessuto danneggiato. Le cellule 
staminali mesenchimali (mesenchymal stem cells, MSCs) hanno attirato l’attenzione dei ricercatori 
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di questo settore come fonte facilmente accessibile di cellule autologhe in grado di differenziarsi in 
vitro in diversi tessuti di origine mesenchimale (ad esempio osseo, cartilagineo, adiposo). Inoltre, 
alcuni studi hanno descritto le proprietà immunomodulatorie e antimicrobiche di queste cellule, 
dimostrando come le MSCs possano limitare la crescita batterica in vivo e come possano 
attivamente modulare la risposta infiammatoria nel sito dell’infezione. Tuttavia, il meccanismo 
d’azione delle MSCs nella modulazione del processo infiammatorio non è ancora chiaro. Un’altra 
importante caratteristica di queste cellule è la loro mancanza del complesso maggiore di 
istocompatibilità II che le rende quindi candidate ideali per il trapianto allogenico.  
L’obiettivo della seconda fase sperimentale di questo progetto è quello di valutare l’efficacia di un 
innovativo hydrogel arricchito di vancomicina, nel prevenire lo sviluppo di una pseudoartrosi 
settica e allo stesso momento favorire la rigenerazione del tessuto osseo. L’utilizzo locale 
dell’hydrogel è stato comparato all’uso di vancomicina per via sistemica, essendo un trattamento 
standard in clinica in caso di infezione da batteri meticillino-resistenti.  
Parallelamente all’interno dello stesso disegno sperimentale, abbiamo valutato l’efficacia 
dell’utilizzo di BMSCs, cellule mesenchimale da midollo osseo, per il controllo della risposta 
infiammatoria e della diffusione della crescita batterica in vivo. In particolare, ratti 
immunocompetenti sono stati sottoposti a una frattura femorale infettata con MRSE e, 
successivamente, inoculati con BMSCs per via sistemica o locale a seconda del gruppo di 
appartenenza degli animali. Scopo dello studio non solo è stato quello di analizzare gli effetti 
immunomodulatori delle BMSCs attraverso la valutazione dei livelli di espressione di citochine 
infiammatorie, ma anche valutare le proprietà osteoinduttive delle BMSCs in grado di produrre 
matrice extracellulare nel tessuto danneggiato. Anche in questo caso l’uso sistemico di cellule è 
stato paragonato a quello locale con il fine di stabilire una via di somministrazione sicura.  
Per tutta la prima fase del progetto di dottorato si è ricercata una strategia in grado di impedire la 
colonizzazione batterica dell’impianto. Tuttavia, il nostro modello animale non è stato in grado di 
fornirci informazioni su come l’infezione sia stata debellata dall’organismo e quali sono stati i 
meccanismi attivati che hanno permesso l’eradicazione dell’infezione e della guarigione della 
frattura. Perché i batteri non sono stati più in grado di formare biofilm in presenza dei trattamenti? 
Pertanto, per rispondere a questa domanda sperimentale, nell’ultima fase del progetto di dottorato 
l’attenzione si è spostata sull’analisi del proteoma di S. epidermidis per capire i meccanismi 
molecolari che i batteri attivano quando formano e stabiliscono biofilm in vitro su inserti di titanio. 
Il percorso che regola la formazione del biofilm in vivo non è ancora completamente noto, ma è 
stato ampiamente studiato e descritto; diversamente troviamo in letteratura poche informazioni sul 
biofilm maturo. Pertanto, con lo scopo di individuare la chiave della stabilità del biofilm maturo, le 
proteine espresse da due ceppi di S. epidermidis coltivati sia in forma planctonica sia in forma 
sessile sono state studiate. In particolare, abbiamo concentrato la nostra attenzione sul ceppo clinico 
GOI1153754-03-14 e comparato la sua espressione di proteine con quelle espresse da S. 
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epidermidis ATCC 35984, considerato il ceppo standard e cui sequenza genomica è già stata 
studiata e depositata in banca dati. Infatti, punto cruciale dell’analisi del proteoma dei batteri è la 
conoscenza del loro genoma. Perciò, per prima cosa, l’intera genoma di S. epidermidis 
GOI1153754-03-14 è stato sequenziato e successivamente depositato in banca dati. La presenza 
dell’intera sequenza genomica di un isolato clinico è cruciale sia per le nostre successive analisi, 
ma permetterà anche di avere una maggiora conoscenza dei ceppi clinici coinvolti in infezioni 
ortopediche.  
A seguito di questa fase preliminare necessaria, S. epidermidis GOI1153754-03-14 e ATCC 35984 
sono stati staticamente coltivati in forma planctonica e in biofilm formante per 72 ore. La coltura 
sessile è stata condotta su dischetti di titanio sabbiato per permettere l’adesione dei batteri e la 
formazione di biofilm; al contrario la coltura planctonica è stata realizzata in agitazione per 
prevenire l’aggregazione delle cellule. I batteri poi sono stati prelevati e dopo vari lavaggi, mirati a 
eliminare i residui del brodo di coltura, sono stati lisati per poter estrarre le proteine. Dopo la 
quantificazione, le proteine sono state prima divise secondo punto isoelettrico e poi secondo peso 
molecolare per ottenere mappe bidimensionali contenenti singoli spot associati a una singola 
proteina. Gli spot statisticamente differenti sono stati poi staccati e le proteine identificate per 
mezzo di analisi di spettrometria di massa. Le analisi hanno rivelato l’incremento di espressione di 
geni legati allo stress cellulare in batteri coltivati in forma planctonica. La coltura a 72 ore ha reso 
possibile la formazione di biofilm sulla superficie del dischetto di titanio, ma allo stesso modo ha 
pregiudicato la crescita degli stessi in forma planctonica. La scelta del time point sperimentale in 
questo studio rappresenta la maggiore limitazione, ma allo stesso tempo un punto di partenza per 
valutare il proteoma di S. epidermidis a diversi tempi per lo studio dell’attivazione/repressione di 
geni coinvolti nella formazione e maturazione della matrice. Lo scopo principale di quest’ultima 
fase del progetto di dottorato e di futuri studi è quello di definire potenziali bersagli molecolari di 
innovative terapie o di definire nuovi biomarcatori diagnostici, tramite l’analisi delle proteine 
espresse dai batteri in determinate condizioni di crescita.  
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Abstract 
 
Non-union fractures, as a severe failure of bone healing, are among the most difficult and 
challenging orthopedic complications. Non-unions represent a clinical burden, as well as a socio-
economic encumbrance that decreases the quality of patients’ lives and requires surgical treatment 
and long recovery times which increases the burden on the National Health Service. The percentage 
of fractures leading to non-union is between 5 and 10% and generally occurs in long bones like 
tibia, femur, humerus, radius, and ulna.  Non-unions are strictly related to local bone loss caused, 
for example, by trauma or tumors; they may depend on patient health status (e.g. age, metabolic 
disease, comorbidities). In addition, they are frequently caused by bacterial infections established 
during surgical procedures (e.g. osteosynthesis, open fractures) and are referred to septic or infected 
non-unions.   
The most common bacteria involved in infected non-unions are Staphylococcus aureus and 
Staphylococcus epidermidis and bacterial contamination accounts for the two-thirds of the clinical 
cases. In particular, S. epidermidis is of utmost importance, being one of the most significant 
bacteria related to hospital-acquired infections. S. epidermidis is an inhabitant of healthy human 
skin and mucosal flora and it is a commensal bacterium characterized by a low pathogenic potential. 
However, this pathogen has emerged as a common cause of numerous nosocomial infections 
associated with medical devices (e.g. catheters, pacemaker, metal implants, etc.), because of its 
capability to create a protective niche on the surface of implanted orthopedic devices, called 
biofilm. Biofilm is a thick matrix of extracellular polymeric substances derived from sessile bacteria 
irreversibly attached to a substratum. Within the biofilm, microorganisms establish organized 
hierarchies similar to that of multicellular organisms; cell-to-cell signaling regulates the expression 
of genes involved in survival mechanisms, depending on environmental influences. Thus, biofilm 
confers a protective niche to pathogens in which they can grow and evade host immune defenses 
and antimicrobial treatments, leading to the development of antimicrobial-resistant strains, such as 
methicillin-resistant S. epidermidis (MRSE). 
Moreover, because of the ubiquitous prevalence of S. epidermidis as a commensal bacterium on 
human skin, it is often difficult to discern whether a clinical isolate represents the causative agent 
of an infection or an unspecific culture contaminant. 
In order to study S. epidermidis-associated infections in orthopedic implants, animal models are 
extremely useful to investigate the pathogenesis of biofilm-related non-union, with particular regard 
to subclinical infections.  
For the aforementioned reason and to fulfill the lack of knowledge in the literature, we established 
a preclinical model of methicillin-resistant S. epidermidis non-union in order to assess the role of 
subclinical infections in orthopedic and trauma surgery. Indeed, an animal model of infected non-
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union able to resemble the features of a nosocomial implant-associated infection was generated, in 
order to investigate new preventive or therapeutic options. Thus, we evaluated the incidence of 
infected non-unions caused by dose-dependent concentrations of methicillin-resistant S. 
epidermidis (MRSE) in rats subjected to femoral fracture osteosynthesis with metal implants. At 
the end of the first experimental phase, we identified the lowest bacterial load of MRSE able to 
induce a clinical infected non-union. In particular, we determined that a low grade bacterial 
injection determines a subclinical infection, whereas the intermediate grade inoculum determines a 
clear acute clinical infection and the highest bacterial inoculum is able to form a visible biofilm 
upon the implant surface, impeding fracture healing in all the treated animals. 
The development of a valid animal model is crucial for the subsequent experimental phases, 
allowing us to study the complex physiopathology of non-unions caused by microorganisms in 
order to optimize therapeutic strategies. 
To treat non-unions, several therapeutic approaches are described in the literature, such as surgical 
debridement or local or systemic antibiotic therapies. Recently, also bone tissue engineers are 
developing biological or synthetic scaffolds with osteoinductive and antibacterial proprieties. 
However, most of these innovative materials used as drug delivery may have some drawbacks, 
including non-biodegradability, possible microbial adhesion and biofilm formation on their 
surfaces, restricted range of loadable antibiotics and long-lasting release with a potential increase 
of antibiotic resistance. Because of these limitations, hydrogels represent promising and potential 
alternative materials able to deliver antibiotics, growth factors or cells locally, while inducing 
osteogenesis and regulating bacterial bone infections associated with orthopedic devices. Recently, 
an innovative hydrogel composed of two biocompatible polymers (hyaluronic acid and poly-lactic 
acid) was tested in vitro and subsequently validated in vivo, as a bio-resorbable barrier against 
infections. However, it is not known yet if this hydrogel also possesses osteoinductive and/or 
osteoconductive properties. Moreover, in the last few years, bone tissue engineering and cell-based 
therapies reported some impressive results in the regeneration of organs or tissues, as well as in the 
treatment of non-septic non-unions. The cell therapy approach aims to deliver healthy cells able to 
produce new calcified matrix within the damaged tissue in order to fix the loss of function. 
Mesenchymal stromal cells (MSCs) have prompted significant interest in biomedical research and 
cell-based therapies due to their ability to self-renew, differentiate in vitro into mesenchymal 
tissues, such as bone, cartilage, or fat and as an easily accessible source of autologous cells. 
Furthermore, some recent studies demonstrated the immunomodulatory and antimicrobial features 
of MSCs.  
Finally, recent studies demonstrated that MSCs can limit bacterial growth in vivo thanks to the 
aforementioned proprieties able to modulate the inflammatory response and macrophage activation 
at the site of infection. Nevertheless, the mechanism of action of MSCs in the modulation of the 
inflammatory process is still unclear.  
Abstract 
10 
Finally, the lack of the major histocompatibility complex II (MHC II) in MSCs could permit the 
allogeneic transplant of these cells.  
Aiming at testing innovative preventive and/or therapeutic strategies through our model of septic 
non-unions, the goal of the second experimental phase was to evaluate the efficacy of an innovative 
hydrogel, with presumed osteoinductive and antibacterial proprieties, to prevent and control the 
progression of bacterial biofilm formation in infected non-unions. Along with this goal, we 
investigated the feasibility and the efficacy of MSCs-based therapy to control both the inflammatory 
response and bacterial growth/spread in vivo. Specifically, immunocompetent rats, already exposed 
to a femoral fracture infected with MRSE, were inoculated with allogeneic mesenchymal stem cells 
isolated from the bone marrow (BMSCs) through two different administration routes - systemic 
(circulatory system) and local injection (fracture site). Through this study, we evaluated both the 
immunoregulatory effects of BMSCs, but also the osteoinductive proprieties of these cells able to 
produce calcified matrix in the damaged tissue. Similarly, we assessed the ability of an enriched 
hydrogel to prevent/treat infected non-unions by inhibiting biofilm formation and stimulating bone 
deposition due to its antibacterial and osteoinductive proprieties.  
The overall and anticipated goal of this first part of the project was to establish new therapeutic 
strategies for the prevention and the treatment of infected non-unions, which result in morbidity 
and, sometimes, limb loss in critical patients. These results may have an important impact on the 
treatment of the infected non-union in orthopedics. Moreover, these tested therapeutic strategies 
may also be used synergically to locally deliver cells due to the engineered hydrogel to optimize 
physiological pathways of fracture healing and to control the progress of local 
inflammations/infections. Another potential use of the therapies from this study would be the use 
of animal models affected with comorbidities (e.g. type I and II diabetes) instead of healthy animals, 
in order to translate the findings on complex infections that may occur in orthopedics.  
In the first experimental phase, all efforts were made to discourage bacterial attachment on the 
surface of metallic implants impairing the bacterial “race to the surface” while favoring the 
eradication of the infection and the fracture healing process. However, our animal model of septic 
non-union was unable to elucidate how the infection was suppressed and why bacteria were not 
able to form biofilm in the presence of the hydrogel or BMSCs. Thus, in order to decipher the 
genetic basis of biofilm formation, the second phase of this project focused on the in vitro analysis 
of the proteome of S. epidermidis when growing in planktonic or in sessile forms on sandblasted 
titanium.  
Staphylococcus epidermidis does not encode many pathogenicity islands, and its principal virulent 
property is the ability to establish organized communities which regulate the expression of genes 
involved in the survival mechanisms and biofilm formation on implants. Indeed, biofilm provides 
bacteria the means to evade the host immune defense. However, the complete pathway that 
regulates biofilm in vivo is not well understood.  
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Thus, aiming at defining markers expressed by mature staphylococcal biofilm on metallic implants, 
in the last experimental phase, we analyzed the proteome of two different strains of S. epidermidis 
in both planktonic and sessile forms. In particular, we compared the whole proteomic profile of two 
different S. epidermidis strains, when growing in their planktonic and sessile forms, in a static 
culture system. We focused our attention on S. epidermidis ATCC 35984, a commercially-available 
bacterial species isolated from catheter sepsis and which the genome is already deposited in 
GeneBank, and on methicillin-resistant S. epidermidis GOI1153754-03-14 used in our previous 
studies.  
First, the entire genome of S. epidermidis GOI1153754-03-14 was sequenced using Next 
Generation Sequencing not only to obtain the genome but also to analyze the protein profile. Indeed, 
the whole genome sequence of the clinical isolate was crucial for proteomic analysis in order to 
highlight the functional mechanisms of biofilm formation.  
Then, ATCC 35984 and the clinical isolate GOI1153754-03-14 were statically cultured in their 
planktonic and sessile forms for 72 hours to establish a mature biofilm. The sessile culture was 
carried out on sandblasted titanium disks on which bacteria adhered and formed the biofilm; 
conversely, the planktonic culture was incubated under agitation to prevent cell clustering. Bacteria 
were then recovered, collected and lysed to extract and separate the proteins by pH and molecular 
weight. Differences in the two-dimensional gels were evaluated and the variably expressed spots 
were identified through mass spectrometry analysis. However, data obtained in our study revealed 
that many changes in the protein expression in both S. epidermidis strains occurred when 
planktonically cultured. In particular, the analysis of the proteins expressed by planktonic bacteria 
rafter 72 hours revealed results linked to a bacterial stress condition due to the culture condition.  
A limitation of this experimental setup was the variation of the proteomic profile associated with 
the static culture system. The chosen experimental time point represents a limit of this study, but 
also an important clue for future analyses in which the same proteomic analysis may be carried out 
at different time points in order to overcome the limitation due to the cell density while allowing 
the comparison of their proteome at the same experimental time point.  
The primary purpose of this final part of the research was to define how protein expression varies 
between two different bacterial strains belonging to the same species and how culture conditions 
can modulate these differences. Comparative proteomic analyses may allow the scientific 
community to understand the molecular pathways associated with biofilm formation on implants, 
thus identifying potential therapeutic targets or diagnostic biomarkers. 
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Introduction 
 
Bone fracture and healing 
Bone fractures are common non-lethal consequences of injuries related to vehicle and sports 
accidents, falls or trauma and their rates are doomed to rise with the increase in life expectancy. 
Long bone fractures are notorious for being slow to heal, often requiring months until the 
consolidation is completed [1, 2]. Fracture healing is a complex dynamic process characterized by 
the balance of mechanical and physiological stimuli; the biological environment is influenced by 
the fixation technique used to stabilize the fracture that will determine the outcome of the healing 
process [3]. The biological course of bone fracture healing is characterized by different steps, 
represented in Figure 1 along with the histological pattern depicted in Figure 2.  
 
 
 
 
 
Figure 1. The bone healing process. (A) Hematoma formation around the fracture site; (B) Soft callus 
formation; (C) Hard callus formation; (D) Bone remodeling phase: [Adapted from 
http://philschatz.com/anatomy-book/contents/m46342.html] 
 
Figure 2. Histological pattern of the bone healing process. The different phases of inflammatory process 
are illustrated through Hematoxylin and Eosin (H&E) staining except for the revascularization phase which 
was evaluated through an immunohistochemistry for alpha smooth muscle; The soft callus phase is 
represented by slides of the bone tissue stained with Movat pentachrome staining, while the revascularization 
phase by Saphranine/Von Kossa staining; Finally, the cartilage and woven bone formation in the hard callus 
phase are stained with Movat pentachrome staining [Bucher et al., 2016. DOI: 10.5772/62476].  
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The first, immediate response to fracture is the formation of a hematoma, as the result of blood 
vessel disruption and bone marrow effusion. As soon as the hematoma forms, the inflammatory 
cells reach the fracture site.  
The acute inflammatory response is the first crucial step in the fracture healing process, activating 
the upregulation of angiogenic factors, thus supporting the vascularization of the injured site. Just 
24 hours after the injury, the pro-inflammatory response is counterbalanced by the release of anti-
inflammatory cytokines involved in the recruitment of cells enrolled in the healing of the injured 
tissue [4]. If the acute inflammatory response remains unresolved (e.g. due to a bacterial infection 
at the injury site or to chronic inflammatory diseases), the healing of the fracture can be inhibited 
or, even worse, it may fail [5].  
The second stage of the fracture healing process is characterized by the progressive evolution of 
the hematoma into granulation tissue, followed by the gradual replacement of the latter in a soft 
callus composed of fibrous tissue and cartilage.  
This anabolic phase is characterized by an increase in tissue volume due to the de novo recruitment 
of mesenchymal progenitor cells [6]. Subsequently, these cells differentiate into chondrocytes or 
osteoblasts producing the extracellular matrix and cartilage, while slowly replacing the hematoma 
and filling the fracture gap [4]. Even if soft callus formation confers to fractures an initial stability, 
the bone healing process is not yet completed.  
Progressively, the soft callus is replaced through a process known as endochondral ossification, 
becoming more robust and mechanically rigid: the cartilaginous callus undergoes a process starting 
with mineralization, then resorption and finally replacement by woven bone [7].  
Once the fracture site is restored, the woven bone is then slowly substituted by lamellar bone, 
concluding the process with the last stage: the remodeling phase. The remodeling process is carried 
out by the balance of hard callus resorption by osteoclasts and lamellar bone deposition by 
osteoblasts [7]. This stage finally concludes the process by restoring the mechanical and biological 
function of the bone.  
 
Bone healing impairment and non-union development 
A crucial step in the treatment of diaphyseal bone fractures is the reduction and stabilization of the 
fracture gap. Since the capability of bone to bridge a gap is known to be limited, the stumps must 
be positioned and fixed - the larger the fracture gap the more delayed the healing process [8]. 
Despite the impressive regenerative capability of skeletal tissue, the bone healing process may fail 
leading to a delay of tissue recovery or even worse to the development of non-unions.  
Non-unions, a severe failure of bone healing, are among the most difficult and challenging 
orthopedic complications. Physiologically, the fracture healing process is completed after three 
months, while a delayed healing occurs if the recovery exceeds three months, and a non-union if 
healing is not achieved by nine months [9].  
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Non-unions can be classified as hypertrophic or atrophic depending on the imbalance between 
biological and mechanical factors (Figure 3).  
 
 
Figure 3. Two different fate of non-union fracture. Atrophic and hypertrophic non-unions as the result of 
an imbalance between biology and stability.  
 
The hypertrophic non-union is a hypervascularized, viable fracture caused by inadequate fixation; 
the lack of stability results in the failure of endochondral ossification leading to the deposition of 
fibrous tissue within the fracture site. In contrast, the atrophic non-union is an avascular, non-viable 
fracture caused by poor vascularization of the site and subsequent insufficient biological response. 
The treatment of atrophic non-unions requires the surgical removal of the dead tissue and its 
replacement with a bone graft, in order to guarantee a prompt biological response in terms of 
vascularization and cell colonization [10]. 
It has been estimated that fracture healing is delayed in 600,000 patients per year in the United 
States alone, and approximately 100,000 of these fractures results in non-unions annually [11]. The 
percentage of fractures leading to non-union is between 5 and 10% [12] and generally occurs in 
long bones like tibia, femur, humerus, radius, and ulna, which are characterized by a slower healing 
process compared to other bones.  
These numbers reflect a socio-economic encumbrance, being associated with prolonged 
hospitalization periods affecting the quality of a patient’s life in terms of loss of productivity and 
earnings, but also in terms of suffering [13]. Nonetheless, these complications result in high 
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economic impact requiring ad hoc health care interventions. In a retrospective study, Antonova and 
colleagues [14] reported the care costs to treat patients with a non-union and without a non-union 
(25,555.97 $ vs. 11,686.24 $, p < 0.001), underlying the need to prevent or reduce the risks of non-
union development. Non-union causative factors have been extensively investigated, and there are 
some important demographic differences between patients whose fractures will heal and those 
whose fractures will fail to recover. Niikura and colleagues [15] classified the cause of non-union 
development as either patient dependent or patient independent factors. Patient dependent factors 
include comorbidities such as diabetes, vascular and metabolic diseases, genetic disorders, 
endocrine pathology and immunodeficiency [15, 16]. Moreover, unhealthy habits largely affect the 
bone healing process. Indeed, it has been recently demonstrated how smoking significantly 
increases the risk of impaired healing process; orthopedists request patients to quit smoking, as an 
essential part of fracture treatment [15, 17]. Moreover, dietary behavior also plays a key role in the 
deficiency of recovery: obesity, alcohol abuse, nutritional deficiency and also the use of 
nonsteroidal anti-inflammatory drugs are all important causative factors [18, 19]. Conversely, 
several elements are independent of patient conduct because they are strictly connected to the type 
of fracture - such as location, displacement - or to the quality of surgical treatment – such as an 
inadequate or deficient mechanical stability that may lead to impaired biological activity [3]. 
Finally, infections are considered an independent factor of utmost importance leading to delayed 
healing or non-union development associated with the loss of function of the affected limb.  
 
Septic non-unions 
Septic non-unions occur in the presence of an infection at the fracture site, impairing the bone 
healing process and affecting the surrounding soft tissues [20]. 
The incidence of these events has been reported in many independent studies, describing a low 
infection rate (1%) after the surgical fixation of closed, low-energy fracture, increasing to 30% in 
complex open fractures [21, 22]. According to the timeline reported in Figure 4, infections after 
fracture fixation can be classified into three categories: early, delayed and late.  
Early infections are mainly caused by high virulence bacteria, like Staphylococcus aureus, and 
usually, they result in an impairment of healing characterized by specific local signs of 
inflammation such as heat, pain, redness, and swelling leading to systemic symptom such as fever 
and lethargy [23]. When patients present these unequivocal signs of infection, a prompt diagnosis 
and treatment of the pathology are provided, ensuing in a quick recovery.  
Conversely, delayed infections generally occur 2-10 weeks after fracture fixation and present signs 
comparable to those of late infections (<10 weeks). These infections are usually due to low-
virulence pathogens like Staphylococcus epidermidis or Propionibacterium acnes, able to adhere 
to the implant surface and remain protected by the surrounding environment, due to biofilm 
formation.  
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Figure 4. Time course of the progression of infections after fracture fixation. The timeline depicts the 
progression of the infection according to the progression of time. Along with the temporal steps, the 
therapeutic strategies of the different stages are reported. 
 
As infection progresses, maturing biofilms provide bacteria the means to evade the host immune 
defense and to develop antibiotic resistance, thus leading to resistant pathogens (e.g. methicillin-
resistant S. epidermidis, MRSE). Indeed, this protective environment favors gene transfer among 
these prokaryotic communities, resulting in an increase in the number of virulence factors [24]. In 
contrast to early infections associated with specific acute signs, delayed and late infections are 
clinically silent events hardly distinguishable from aseptic prosthetic failure [22, 25, 26]. 
Among several pathogens involved in implant-related infections, staphylococci account for two-
thirds of the clinical cases [27, 28]. Most of the clinical isolates are highly virulent pathogens, such 
as Staphylococcus aureus (35.5%), Escherichia coli (3%) or Pseudomonas aeruginosa (4-6%), 
while the low virulence pathogens usually involved are S. epidermidis (27.5%) and P. acnes (10%) 
[29].  
In particular, S. epidermidis has recently emerged as a common cause of numerous nosocomial 
infections associated with medical devices (e.g. catheters, pacemaker, metal implants, etc.) 
particularly in immunocompromised patients and infants [30]. This is mainly due to the presence 
of S. epidermidis on healthy human skin and mucosal flora where it lives as a commensal bacterium. 
Interestingly, the skin of healthy people is colonized by 10-24 different strains of S. epidermidis at 
any time. The host-bacteria bond is mutually beneficial; it impairs the attachment of more virulent 
Introduction 
17 
bacteria through a mechanism called bacterial competition while conferring the ideal habitat for 
bacterial growth [31]. S. epidermidis is a commensal Gram positive, coagulase negative, non-spore-
forming bacterial species and, depending on the biological context in which it grows, it could be 
either a symbiont or a pathogen implicated in delayed infections characterized by the absence of 
specific clinical signs [29]. Moreover, due to the ubiquitous presence of S. epidermidis as a 
commensal species on human skin, it is often difficult to distinguish whether a clinical isolate 
represents the causative agent of the infection or an unspecific culture contamination [30]. In 
contrast to S. aureus, S. epidermidis does not encode many pathogenicity islands, and its major 
virulent property is the ability to establish organized communities which regulate the expression of 
genes involved in survival mechanisms and biofilm formation on implants [31, 32].  
 
Bacterial biofilm 
The presence of a foreign body is the triggering event for staphylococcal infections, because it 
permits bacterial attachment and biofilm formation, making the eradication of the infection difficult 
[33, 34].  
 
 
Figure 5. Representation of the clinical interaction between host, implant and antibacterial prophylaxis 
in the presence of biofilm-forming bacteria. (A) Subclinical scenario in which bacteria do not interfere in 
any detectable way with implant function; (B) Implant malfunction defined by minor clinical signs of 
infection; (C) Low-grade infection characterized by a mild host reaction and moderate clinical signs of 
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infection; (D) High-grade infection. in which acute signs and symptoms of infection and inflammation are 
present. [Romanò et al., 2017. DOI: 10.1007/5584_2016_158] 
 
Bacteria preferentially adhere and form biofilm on rough surfaces, because surface irregularities 
maximize contact area while protecting the pathogens from shear forces [35]. 
Therefore, biofilm plays a crucial role in the pathogenesis of implant-related infections. In Figure 
5 clinical scenarios in the presence of an implant contaminated with biofilm-producing 
microorganisms are outlined. 
An early description of bacterial biofilm was presented by Costerton and colleagues in 1978 [36]. 
in which they described biofilm formation as an evolutionary mechanism that allows bacteria to 
survive in competitive environments, which favors the selection of pathogens protected from the 
external ecosystem [36]. Indeed, adhesion to a tissue or to the surface of an implant and subsequent 
biofilm formation enable bacteria to live in a protected environment with renewed nutrient supply, 
without being affected by fluid stream shear or by the host immune system. Microbial biofilm is 
defined as a population of microorganisms attached to a surface and surrounded by extracellular 
polymeric substance (EPS) matrix, composed of polysaccharides, proteins and nucleic acids [37]. 
Indeed, sessile bacteria grow as microcolonies enclosed in a thick matrix interspersed with open 
water channels. The biofilm is a complex dynamic environment and, the process that leads to its 
formation has been extensively studied and divided into five progressive steps involving bacterial 
attachment, aggregation, accumulation, maturation, and detachment (Figure 6) [38].  
 
 
Figure 6. Representative illustration of the phases of biofilm formation. (1) Bacterial attachment; (2) 
Aggregation; (3) Accumulation; (4) Maturation and (5) Detachment [Sauer, 2003. DOI: 10.1186/gb-2003-4-
6-219] 
 
As soon as contamination occurs, the “race to the surface” begins as first described by Gristina and 
colleagues, determining the fate of the development of the infection [39]. If the race to the surface 
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is won by cells of the surrounding tissue, the implant surface will be occupied and, therefore, 
defended. Otherwise, if the race is won by bacteria, they rapidly adhere to the biomaterial and 
colonize the surface due to several physicochemical interactions (e.g. van der Waals and 
gravitational forces, electrostatic repulsion, and ionic and dipole interactions). Thereafter, bacteria 
start to proliferate and aggregate in clusters through cell-to-cell adhesion; guided by molecular 
signaling, they secrete EPS to form a multi-layered structured biofilm [33, 40]. 
These micro colonies can remain quietly embedded in biofilm for extended periods of time until 
the environment allows them to overgrow or until detachment of single cells or larger cell clusters 
occurs [35]. Biofilm detachment is a crucial evolutionary phase of the infection process since it 
allows the dissemination of bacteria and, consequently, the colonization of other sites within the 
host [38]. Several factors may contribute to the detachment of single cells or larger bacterial clusters 
such as mechanical forces from bloodstream flow or chemical stimuli, such as the transcription of 
protease or the inhibition of the production of exopolysaccharide [38].  
However, the entire pathway that regulates biofilm formation in vivo is still unknown due to the 
complex interaction between the host and microorganisms. For the latter reason, in vitro studies 
cannot entirely mimic the in vivo environment. Hence, there is a real need to investigate the 
pathogenesis of orthopedic infections mediated by biofilm formation through in vivo animal models 
[41].  
 
Animal models of implant-related infections  
Several animal models have been established to study osteomyelitis or implant-related infections 
in terms of pathogenesis, development, and diagnosis. Models have been used also to investigate 
host response to novel therapeutic or preventive approaches to fight implant-related infections. 
However, animal models which use low –virulence pathogens, such as S. epidermidis and 
Propionibacterium acnes, are poorly described in the literature probably due to their lower 
incidence in orthopedic infections [29]. Indeed, in 2016 a PubMed search was conducted to review 
the existing animal models of implant-related low-grade infections published in the last twenty 
years. Manuscripts were searched using the following keywords: animal model(s) OR preclinical 
model(s) AND orthopedic infection(s) OR osteomyelitis OR prosthetic infection(s). A total of 764 
studies were identified, of which 118 duplicates and 38 non-English studies. As a result, only 45 
articles were considered: 39 describing the use of highly virulent pathogens used at low bacterial 
load and 6 analyzing low virulence pathogens (Figure 7). Of the six articles, only one was focused 
on infection caused by P. acnes and the remaining five on S. epidermidis. However, none described 
or investigated the development of septic non-unions caused by low virulence bacteria, emphasizing 
the lack of knowledge in this field. Therefore, the creation of a valid animal model of low-grade 
non-union is crucial to study the complex physiopathology of non-unions in order to optimize both 
preventive and therapeutic strategies [42].  
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Figure 7. Research strategy. Flow chart of the process of article selection. [Lovati et al., 2017. DOI: 
10.1007/5584_2016_157] 
 
Therapeutic approaches to treat septic non-unions 
Therapeutic approaches to treat septic non-unions described in the literature, include surgical 
debridement of the infected tissue, followed by local or systemic antibiotic therapies [20, 34]. 
Indeed, this two-step procedure is routinely used in clinical practice for the treatment of septic non-
unions; primarily, the infected tissue is eradicated through debridement of the affected bone and 
soft tissues. Then, the resulting gap is reconstructed by means of antibiotic-loaded cement or bone 
graft [43]. Recently, new protocols in bone tissue engineering propose the use of biological or 
synthetic scaffolds with osteoinductive and antibacterial proprieties to handle biofilm-mediated 
infections after surgical debridement [44, 45]. However, most of these innovative materials have 
some drawbacks, including non-biodegradability, the availability to microbial adhesion and 
subsequent biofilm formation on their surfaces, restricted range of loadable antibiotics and long-
lasting release with a possible increase of antibiotic resistance [46]. These limitations highlight the 
need for alternative biodegradable biomaterials which can locally deliver and substantial amounts 
of treatment [47]. Hence, hydrogels represent promising and potential alternative materials to 
locally convey antibiotics, growth factors or cells, while inducing osteogenesis and forestalling 
bacterial infections associated with orthopedic devices [48, 49]. 
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Moreover, in the last few years, bone tissue engineering and cell-based therapy achieved some 
impressive results in the regeneration of organs or tissues, as well as in the treatment of non-septic 
non-unions [50-52]. This cell therapy approach aims at delivering healthy progenitor cells able to 
repair the loss of function of damaged tissues. Mesenchymal stromal cells (MSCs) are promising 
in biomedical research and cell-based therapies due to the ability of these cells to self-renew, 
differentiate in vitro into mesenchymal tissues such as bone, cartilage, or fat and being an readily 
accessible source of autologous cells [53, 54]. Another advantage in the use of MSCs is represented 
by the lack of the major histocompatibility complex II (MHC II) which permits the allogeneic 
transplant of these cells [55]. Furthermore, some recent studies demonstrated the 
immunomodulatory [56-58] and antimicrobial features [59] of MSCs. Indeed, it has been 
demonstrated that MSCs are able to suppress the inflammatory response by inhibiting T cell action 
[60], as well as the inhibition of the maturation of antigen-presenting cells [61]. In particular, MSCs 
have been shown to be effective in the control of the inflammatory processes within tissues and 
organs [62, 63]. In the case of infections, the inflammatory process activates macrophages which 
will produce pro-inflammatory cytokines (e.g. TNFα, IL-1β) [64]. Some authors demonstrated that 
the systemic or local injection of MSCs could down-regulate the release of pro-inflammatory 
cytokines, thus inhibiting inflammation development [63, 65, 66]. In addition to the capability of 
MSCs to modulate pro-inflammatory cytokines, other studies also demonstrated the ability to 
stimulate the production of anti-inflammatory molecules (e.g. IL-10, IL-4) [57]. Nevertheless, the 
mechanism of action of MSCs in the modulation of the inflammatory process is still unclear. 
Finally, recent studies demonstrated that MSCs are able to limit bacterial growth in vivo thanks to 
the aforementioned proprieties which modulate the inflammatory response and macrophage 
activation at the site of infection [63].  
Presently, most tissue engineering strategies aim at discouraging bacterial attachment to the surface 
of metallic implants thereby impairing the bacterial “race to the surface” [67], while favoring the 
eradication of the infection and improving the bone healing process. However, the preclinical 
evaluation of these innovative treatments has some important drawbacks. Indeed, the applied 
models are unable to elucidate how the infection is suppressed and why bacteria are not able to 
form biofilm in the presence of the hydrogel or MSCs. 
As in other branches of medical science, the synergistic study of the same biological mechanism 
by dissimilar disciplines helps researchers to evaluate different aspects that, otherwise, would not 
be taken into consideration  
The investigation of the interaction between the host and microorganisms, is difficult due to the 
enormous number of variables. Therefore, the need to thoroughly understand the mechanisms 
related to these infections and their pathogenesis as related to the causes of bone healing 
impairment, starts from the main cause: biofilm producing bacteria. 
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Molecular approaches to investigate septic non-unions: from genomics to proteomics 
Since its development in 1983, polymerase chain reaction (PCR) technology has been employed in 
microbiological laboratories as an accurate, rapid and sensitive diagnostic tool for the analysis of 
microorganisms in clinical, environmental and food specimens [68].  
In recent years, PCR has been applied to a large number of genome analyses and this technology 
has been widely optimized and modified, according to scientific demands. Indeed, the versatility of 
PCR has led to the development of a number of protocols including Real-Time PCR. This 
quantitative PCR technique analyzes target messenger RNA in a sample, enabling the measurement 
of the expression of a specific gene [69]. Due to the ability to quantify cellular transcript levels, the 
focus of molecular biologists shifted from the study of static composition of the genome to 
functional analysis of the pathways activated by cells under different environmental conditions. 
Indeed, Real-Time PCR analyses are context-dependent because they measure the number of 
mRNA copies depending on the physiological or pathological status of cells [70].  
Additionally, from the time when the first two complete bacterial sequences were published in 1995 
[71, 72], the number of bacterial genome sequences deposited in public databases has increased, as 
a result of the cost reduction triggered by technological and methodological advancement [73]. The 
availability of whole bacterial genome sequences in public databases allowed the study of the 
expression of the entire genome of a microorganism, launching the post-genomic era [74]. Indeed, 
it is now possible to assay the expression of target genes and to evaluate their modulation under 
different growth conditions. In particular, proteomic analyses are capable of comparing proteins 
expressed by microorganisms or cells when they are exposed to various stimuli. Since mRNA levels 
do not necessarily correlate with protein levels, proteomic analysis quantifies up- or downregulated 
proteins to determine their abundance, as well as assessing the presence of post-translational 
modifications (PTMs) enabling the study of their biological roles [75]. Notably, protein activity can 
be modulated by PTMs now known to be implicated in the pathogenesis of some important 
neurodegenerative diseases, such as Alzheimer’s disease [76].  
The aim of the proteomic approach is to extract, separate and identify all the proteins expressed by 
cells in a given experimental setting. Protein identification requires the availability of genome 
information in public databases, including the functional annotation of the target genome. Indeed, 
protein structural information is now available through mass spectrometry (MS), an analytical 
technique able to convert proteins or peptides into ions and to sort them based on their mass-to-
charge ratio [77]. Profiling gene expression patterns in biofilm producing bacteria through omics 
sciences is crucial to decipher the genetic basis of biofilm formation. Thus, it could provide the 
groundwork for the development of new drugs against biofilm-related infections, as well as the 
identification of novel biomarkers [78]. 
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Molecular basis of biofilm formation  
Biofilm-forming bacteria have a gene expression pattern that differs from planktonic forms; various 
genes have been found to be up- or down-regulated during biofilm formation, ranging from 1 to 
38% of the total genome [74]. Likewise, the establishment of staphylococcal biofilm is mediated 
by the activation of different genes, according to the stage of biofilm development. This pathway 
has been studied and divided into progressive steps involving the expression of specific proteins 
during attachment, aggregation, accumulation, maturation, and detachment [38]. Staphylococcal 
attachment is characterized by the expression of proteins related to bacterial adhesion to the surface 
of the device. In this step, wall teichoic acid (WTA), adhesins/autolysins (AltE and Aea), as well 
as the Microbial Surface Components Recognizing Adhesive Matrix Molecules (MSCRAMM’S) 
play a fundamental role in initial attachment [79]. Subsequently, the production of Polysaccharide 
Intercellular Adhesin (PIA)/poly-N- acetylglucosamine (PNAG) contributes to the cell-to-cell 
adhesion process. The synthesis of PIA is regulated by the intercellular adhesion (icaADBC) locus, 
which encodes enzymes able to trigger the synthesis of PNAG in ica-dependent biofilm producers. 
Staphylococci are also capable of producing biofilm through an ica-independent pathway, when 
the icaADBC locus is missing or deleted [33]. In this scenario, biofilm formation in S. epidermidis 
is mediated by adhesive proteins, such as Biofilm Associated Proteins (Bap) and Accumulation 
Associated Protein (Aap) [33]. It has been described that up to 27% of S. epidermidis clinical 
isolates characterized as being biofilm producers are ica-dependent pathogens [79]. The 
extracellular matrix produced in the accumulation stage is mainly composed of exopolysaccharides 
(PNAG), proteins (e.g. Bap, Aap, and fibronectin-binding proteins, FnBPs), extracellular DNA and 
surface proteins (e.g. cell-wall anchored protein, CWA) [79].  
Finally, in the detachment stage, bacteria separate from the mature matrix and disperse throughout 
the host. Bacterial embedded in biofilm secrete signal molecules which permit the cell-to-cell 
communication, called quorum sensing involved in the control of a large number of biological 
processes, including the detachment phase [79].  
An in vivo study demonstrated how this phase depends on a well-characterized quorum-sensing 
system (accessory gene regulator, agr), through agr mutant bacteria in a rabbit model of medical 
device–related infection [80]. Indeed, the quorum-sensing system agr is involved in the up-
regulation of acute virulence factors and in the simultaneous down-regulation of surface protein 
expression involved in bacterial attachment [38]. The quorum-sensing system agr is modulated by 
cell-to-cell communication, triggering the synthesis of phenol soluble modulins (PSMs), alpha-
helical ampholytes (Figure 8) [81]. The expression of PSMs represents an essential virulence factor 
of S. epidermidis, leading to the shift between an aggressive and silent form during staphylococcal 
infections [78]. Moreover, PSMs not only are implicated in the spread of the infection due to biofilm 
detachment but they also are involved in the lysis of red and white blood cells and neutrophils, 
stimulating the inflammatory response [82]. 
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Figure 8. Schematic quorum sensing-agr pathway. [Adapted from Kırmusaoğlu 2016. DOI: 
10.5772/62943] 
 
In S. epidermidis-mediated infections, biofilm production is strictly related to the environmental 
conditions in which bacteria grow, such as culture media composition and supplements, the 
presence of iron ions, salt stress and oxygen [79]. Indeed, both genetic and environmental influences 
have an impact on biofilm formation; bacteria can adapt to different growing conditions by 
modulating their biofilm structure [24]. To fully comprehend how nutrients and the mechanical 
environment (e.g. shear stress) acts or interferes with biofilm formation requires the study of biofilm 
physiology in greater detail to determine the molecular basis for the development of anti-
staphylococcal drugs and treatments.  
 
Future prospective in anti-biofilm therapies  
The study of virulence factors and regulatory mechanisms correlated to biofilm-mediated infections 
may encourage the development of innovative therapeutic strategies, to discourage implant 
bacterial colonization at the molecular level. Clearly, all the strategies proposed and conceived so 
far have not been sufficient to reduce this severe complication.  
The primary intention of orthopedic devices is to provide mechanical stabilization and 
osseointegration, to quickly restore the physiological function of the injured limb, while limiting 
the risk of infections. For this reason, biomaterials used in clinics are rigorously regulated by the 
International Organization for Standardization (ISO) and the American Society for Testing and 
Materials (ASTM) [83]. 
In order to improve implant osseointegration, orthopedic devices have various degrees of surface 
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roughness. The modification of the surface not only plays a role in implant integration but may also 
facilitate bacterial adhesion leading to infections [83, 84]. Some studies evaluated the bacterial 
capability to adhere on metal alloys, identifying a range of roughness and establishing a minimum 
threshold to avoid colonization. Theoretically, biofilm formation can be impaired by means of 
smoothing the implant surface [81]. However, this adjustment may delay the integration of the 
implant, reducing its function.  
To overcome this main drawback, many efforts have been devoted to the development of coatings 
able to interfere with the early stages of biofilm formation by preventing bacterial attachment.  
Currently, there is not a universally accepted classification of coating technologies because of the 
lack of regulatory aspects and standardized validation methods [85]. However, according to their 
mechanisms of action, coatings can be classified as passive or active surface modifications (PSM 
and ASM, respectively), or as peri-operative antibacterial local carriers (LCC) (Figure 9).  
 
 
Figure 9. A representative illustration of implant coating mechanisms of action.  
 
Specifically, PSM impedes bacterial adhesion or directly kills pathogens upon contact through 
chemical or physical alterations of the surface, without the release of antimicrobial agents or 
antibiotics. In contrast, ASM acts by locally delivering antibiotics or bactericidal agents such as 
metal ions, or organic and inorganic compounds [86, 87]. Finally, LCC are usually biodegradable 
barriers able to locally deliver high concentrations of antibacterial in a restricted temporal window 
[85]. Presently, there are different coatings available in the orthopedic marketplace. However, there 
are several issues related to their application. Specifically, these include dosage, release kinetics, 
stability, and biodegradation rates which may lead to antibiotic resistance or alteration in the local 
microbiologic flora [86].  
The development of new molecular techniques, in the last few years make it possible to identify 
new markers of infections, together with new therapeutic targets or vaccines [88].  
This innovation could provide the basis for novel strategies for targeting bacterial biofilm 
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determinants including blocking the synthesis of PIA/PNAG [79], or developing anti-QS treatments 
and/or biofilm dispersal agents [88] or identifying new vaccines against MASCRAMMs [89] or 
PSMs [82]. There are no FDA approved vaccines for the treatment of staphylococcal infections 
[81]. Thus, there is the need for intensive molecular research focused on biofilm-mediated infection 
in order to develop a safe, broad-spectrum preventive or therapeutic approach.  
Last but not least, the prophylaxis of implant-related infections in hospital settings should be 
emphasized [81]. Orthopedic operations are an extremely risky surgery, due to prolonged 
intervention, massive blood loss and due to the implant of foreign bodies, thus requiring an ultra-
clean environment [90]. Simple protocols can avoid debilitating consequences, such as the 
installation of equipment like laminar air flow and/or ultraviolet light can significantly reduce the 
risks of airborne and non-airborne bacterial contaminations [91]. Moreover, orthopedic surgical 
teams must reconsider the importance of skin disinfection and decontamination of surgical 
instruments or orthopedic materials [90]. This central issue could only be accomplished by the 
surgeons thorough understanding of the factors that may contribute to infection development. 
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Aim of the study 
 
The introduction section reviewed current knowledge concerning the development of septic non-
unions while describing the central role of bacterial biofilm and the need to counteract biofilm 
formation on orthopedic implants. The mechanisms related to biofilm-mediated infections could be 
elucidated with the creation of new animal models. However, in the literature, there are few animal 
models which describe the use of low virulence pathogens, such as S. epidermidis.  
To address these issues, the first aim of the project was to develop a preclinical model of infected 
non-union able to resemble the features of a nosocomial implant-associated infection, in order to 
investigate new preventive or therapeutic options (Chapter 1). We evaluated the incidence of 
infected non-unions caused by different cell concentrations of methicillin-resistant S. epidermidis 
(MRSE) in rats that underwent femoral fractures synthesized with metal implants.  
The development of a valid animal model was crucial for the subsequent experimental phase. 
Indeed, the second aim was focused on the evaluation of innovative preventive and/or therapeutic 
strategies using the preclinical model developed in aim 1 above (Chapter 2). In particular, the rat 
model of the sub-acute onset – infected with 105 CFU MRSE - was chosen and used to test the 
efficacy of a local antibiotic therapy delivered through a hydrogel with osteoinductive and 
antibacterial proprieties. Moreover, the same model was used to test the feasibility of a cell-based 
approach, by the systemic or local injection of undifferentiated allogeneic BMSCs. The overall goal 
of this first part of the project was to examine potential therapeutic strategies for the prevention and 
the treatment of infected non-unions. 
The second aim of the project was to decipher the genetic basis of biofilm formation through the in 
vitro analysis of the proteome of two different strains of S. epidermidis growing as sessile or 
planktonic forms. First, in order to appropriately identify the changes in the proteomic profile of S. 
epidermidis GOI1153754-03-14, the whole genome of this bacterium was sequenced through next 
generation sequencing analysis and the sequence was deposited in the DDBJ/ENA/GenBank 
database under the accession number FWCG01000000 (Chapter 3).  
Thereafter, the second part of the aim compared the proteomic profiles of S. epidermidis ATCC 
35984, and the clinical isolate GOI1153754-03-14 statically cultured in their planktonic and sessile 
forms (Chapter 4). Through this study design, we were able to evaluate the changes in the proteomic 
profiles as the result of biofilm maturation on titanium in a static environment.  
The primary purpose of the final chapter was to define how protein expression varied between two 
different bacterial strains belonging to the same species while determining how the culture 
conditions can modulate these differences. Comparative proteomic analyses may enable the 
scientific community to understand the molecular pathways associated with biofilm formation on 
implants and identify future therapeutic targets or diagnostic biomarkers. 
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Abstract 
 
S. epidermidis is one of the leading causes of orthopedic infections associated with biofilm 
formation on implant devices. Open fractures are at risk of S. epidermidis transcutaneous 
contamination leading to higher non-union development compared to closed fractures. Although 
the role of infection in delaying fracture healing is well recognized, no in vivo models investigated 
the impact of subclinical low-grade infections on bone repair and non-union. We hypothesized that 
the non-union rate is directly related to the load of this commonly retrieved pathogen and that a 
low-grade contamination delays the fracture healing without clinically detectable infection. Rat 
femurs were osteotomized and stabilized with plates. Fractures were infected with a characterized 
clinical-derived methicillin-resistant S. epidermidis (103, 105, 108 colonies forming units) and 
compared to uninfected controls. After 56 days, bone healing and osteomyelitis were clinically 
assessed and further evaluated by micro-CT, microbiological and histological analyses. The biofilm 
formation was visualized by scanning electron microscopy. 
The control group showed no signs of infection and a complete bone healing. The 103 group 
displayed variable response to infection with a 67%of altered bone healing and positive bacterial 
cultures, despite no clinical signs of infection present. The 105 and 108 groups showed severe signs 
of osteomyelitis and a non-union rate of 83–100%, respectively. The cortical bone reaction related 
to the periosteal elevation in the control group and the metal scattering detected by micro-CT 
represented limitations of this study. Our model showed that an intraoperative low-grade S. 
epidermidis contamination might prevent the bone healing, even in the absence of infectious signs. 
Our findings also pointed out a dose-dependent effect between the S. epidermidis inoculum and 
non-union rate. This pilot study identifies a relevant preclinical model to assess the role of 
subclinical infections in orthopedic and trauma surgery and to test specifically designed diagnostic, 
prevention and therapeutic strategies. 
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Introduction 
 
Fracture non-unions represent a great clinic and surgical challenge, in particular when associated 
with bacterial infections. Septic delayed- or non-union fractures have limited and often difficult 
treatment options, requiring prolonged hospitalization and antibiotic therapy, with a high 
socioeconomic impact [1, 2]. Although the development of a fracture non-union depends on many 
factors, including the type and site of fracture, the treatment and host response, open fractures are 
definitely at higher risk of non-union — 5% to 100%, depending on the degree of exposure and 
contamination [3] — than those undergoing osteosynthesis for closed, not contaminated fractures 
(1 – 2%) [4, 5]. Although this observation points out the direct relationship between fracture 
contamination, infection and non-union development, we currently have no animal models or data 
from human studies concerning the impact of subclinical, low-grade infections on bone healing and 
non-union. Sporadic clinical observations showed that low-virulent pathogens, like certain 
coagulase-negative staphylococci, might be related to non-unions or pain at the fracture site even 
in the absence of clinical signs of infection [6]. Staphylococcus aureus and Staphylococcus 
epidermidis are the most common pathogens involved in orthopaedic infections and account for 70 
– 90% of the cases after elective surgery [7]. S. epidermidis is a harmless commensal inhabitant of 
human skin lacking the capability to penetrate the host [8]. Therefore, the S. epidermidis-related 
infection is caused by its delivery from the skin to the host tissues in case of open fractures and 
surgical procedures [9]. S. epidermidis is also one of the leading causes of infections associated 
with biofilm formation because of its high ability to adhere and colonize implant medical devices, 
such as catheters, heart valves and orthopaedic prosthesis [10-12]. The biofilm formation in S. 
epidermidis orthopaedic infections makes less effective the antimicrobial treatment and increases 
the emergence of antibiotic-resistant strains such as methicillin-resistant S. epidermidis (MRSE), a 
common osteomyelitis-inducing pathogen [13]. 
Concerning the consequence of S. epidermidis-associated infections in orthopaedic implants, 
animal models are mandatory to investigate the pathogenesis of non-union-related infections, with 
particular reference to subclinical infections. To our knowledge, there are many rodent models of 
osteomyelitis and septic arthritis, but only few studies did investigate the fracture repair in the 
presence of S. aureus infection by performing critical defects in long bones [1, 14-17], while no 
modeling of S. epidermidis implant-related infection in osteosynthesis has been described so far. 
Specifically, a few studies did investigate clinical MRSE strains in developing intravascular or 
urinary tract infections [18-20] as well as in wound healing and in subcutaneous models [9, 21]. 
Animal models of prosthetic joint and medullary canal infections have also been studied 
associating a clinical MRSE strain to stainless steel implants [22-24]. To the best of our knowledge, 
there is not a suitable animal model to mimic MRSE-induced non-union fractures. Moreover, there 
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are no data concerning the effect of low bacteria inocula on fracture healing after osteosynthesis. 
Our hypothesis is that the rate of non-union, induced by a commonly isolated pathogen, like S. 
epidermidis, is directly related to the inoculated bacterial load and that very low bacterial inocula 
may be associated with a higher rate of non-union development compared to uninfected controls, 
despite the absence of local or general signs or symptoms of a post-surgical infection. 
For the first time, we propose a rat model of dose-dependent MRSE-induced non-union synthesized 
with metal implants both to demonstrate the role of subclinical infections in impairing the fracture 
healing and to create a model useful to investigate novel treatments for non-unions. 
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Materials and Methods 
 
Ethics Statement  
The whole study was approved by the Mario Negri Institute for Pharmacological Research 
(IRFMN) Animal Care and Use Committee (IACUC) (Permit N. 06/2014-PR). The animals were 
housed at the Institute's Animal Care Facilities that meet international standards. The IRFMN 
adheres to the principles set out in the following laws, regulations, and policies governing the care 
and use of laboratory animals: Italian Governing Law (D.lgs 26/2014; Authorization n.19/2008-A 
issued March 6, 2008 by Ministry of Health); Mario Negri Institutional Regulations and Policies 
providing internal authorization for persons conducting animal experiments (Quality Management 
System Certificate–UNI EN ISO 9001:2008 –Reg. N° 6121); the NIH Guide for the Care and Use 
of Laboratory Animals (2011 edition) and EU directives and guidelines (EEC Council Directive 
2010/63/UE). The Statement of Compliance (Assurance) with the Public Health Service (PHS) 
Policy on Human Care and Use of Laboratory Animals has been recently reviewed (9/9/2014) and 
will expire on September 30, 2019 (Animal Welfare Assurance #A5023-01). The animals were 
regularly checked by a certified veterinarian responsible for health monitoring, animal welfare 
supervision, experimental protocols and procedure revision. All surgeries were performed under 
general anesthesia, and all efforts were made to minimize suffering. 
 
Study design 
Twenty-four 12-weeks-old Wistar male rats weighing 300–350 g (Harlan, Italy) were included in 
this study. The rats were randomly assigned to one of the experimental groups (n = 6 each group): 
the control group (CTRL) was injected with 30 µl phosphate-buffered saline (PBS); the 103 MRSE, 
105 MRSE, and 108 MRSE groups were injected with 30 µl of a bacterial suspension containing 
103, 105, and 108 colonies forming units (CFU) of MRSE, respectively. After 8 weeks, micro-CT 
scanning, microbiological and histological analyses were performed to assess the bone healing and 
infection, and Scanning Electron Microscopy (SEM) was carried out to visualize the biofilm 
formation. 
 
Bacterial strain characterization 
The MRSE strain GOI1153754-03-14 used in this study was isolated at the Laboratory of Clinical 
Chemistry and Microbiology (IRCCS Galeazzi Orthopaedic Institute, Milan, Italy). The strain 
derived from infected knee prosthesis of a patient undergone implant revision at the Center for 
Reconstructive Surgery of Osteoarticular Infections (IRCCS Galeazzi Orthopaedic Institute, Milan, 
Italy). This strain was selected for its antibiotic susceptibility pattern and its capacity to produce 
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biofilm on prosthetic materials in vitro. 
 
Identification and antibiotic susceptibility testing 
Microbiological identification was performed at a phenotypic and genotypic level. Phenotypic 
identification carried out on VITEK2 System (Biomerieux, France) was subsequently confirmed 
by pyrosequencing analysis (PSQ96RA, Diatech, Italy) of DNA of variable regions V1 and V3 of 
the 16S rRNA gene by using primers reported in a previous study [25]. Amplified sequences (about 
60–80 bp) were compared with sequences available in BLAST search. Antimicrobial susceptibility 
testing and determination of the minimum inhibitory concentration (MIC) were carried out on 
Vitek2 System using the card AST 632 specific for staphylococci. 
 
Biofilm formation assay by crystal violet staining 
Biofilm production was evaluated according to spectrophotometric assay [26] that was repeated in 
triplicate. Briefly, the MRSE strain was grown on blood agar plates. After overnight incubation at 
37°C in aerobiosis, a 0.5 McFarland suspension was prepared and 20µl aliquots were inoculated in 
96-well plates containing 180 µl of Tryptose Soy Broth (TSB; BioMérieux). After an overnight 
incubation at 37° C in aerobiosis, the medium was refreshed and plates were incubated for a further 
48 hours at 37° C. Un-inoculated wells containing only TSB were used as negative control. At the 
end of incubation, the wells were washed with PBS (Gibco, Italy) to remove bacteria not included 
in biofilm. Once dried, wells were stained with 200 µl of 5 % crystal violet solution (Merck, 
Germany) for 10 minutes, and then washed. After air-drying, 200 µl of absolute ethanol were added 
to solubilize the dye attached to the biofilm. The optical density (OD) of each well was measured 
at 595 nm by using a microplate reader (Multiskan FC, Thermo Scientific, Italy). Strains were 
classified as strong, moderate or weak producers of biofilm, according to criteria defined by 
Stepanovic et al [27], which are based on the comparison between the OD of strain under testing 
and a cut-off value (ODc) defined as three standard deviation above the mean OD of the negative 
control (un-inoculated broth). In particular, if the sample OD (ODs) is less than the ODc, the strain 
is considered as a non-biofilm producer. If the ODs value is comprised between 1 and 2 ODc, the 
strain is classified as a weak producer. If the ODs values is comprised between 2 and 4 ODc, the 
strain is classified as a moderate producer. Finally, if the ODs value is greater than 4 ODc, the strain 
is classified as a strong producer. 
 
Preparation of MRSE for inoculation into the femur fracture 
Previously characterized MRSE strain was cultured onto Mannitol Salt Agar (BioMérieux) at 37° 
C overnight. To prepare the inoculum, a selected colony was cultured into Brain Heart Infusion 
Broth (BHI, BioMérieux) and incubated for 16 hours at 37°C. The bacterial suspension was washed 
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twice and the obtained pellet was suspended in sterile saline to obtain a 10 McFarland turbidity 
equal to about 3×108 CFU/ml. The bacterial suspension was then serially diluted with sterile saline 
solution to obtain the desired bacterial load of 1x103, 1x105 and 1x108 CFU/30 µl. Bacterial inocula 
were verified and confirmed by agar plate counting procedures. The bacterial suspension was used 
within 2 hours and stored at 4° C until use. 
 
In vivo surgical procedures 
Twenty-four 12-weeks old male Wistar rats (mean body weight 337.6 ± 10.2 g) were used for the 
experiments. The rats were maintained in controlled conditions of temperature and lightning and 
fed with autoclaved food and water provided ad libitum. All pre-surgical and surgical procedures 
on the animals were performed under a laminar flow hood. The rats were anesthetized via inhalation 
of isoflurane (3 %; Merial, Italy) and maintained with an intraperitoneal injection of ketamine 
hydrochloride (80 mg/kg; Imalgene, Merial) and medetomidine hydrochloride (1 mg/kg; Domitor, 
Pfizer, Italy). All animals received a preoperative intramuscular single injection of cefazolin (30 
mg/kg; Cefamezin, Teva, Italy) and a subcutaneous treatment with carprofen (5 mg/kg; Rimadyl, 
Pfizer). Using aseptic technique, all rats were submitted to a midshaft osteotomy of the right femur. 
Briefly, after shaving and disinfection, a longitudinal 2.5 cm skin incision was performed through 
a lateral approach to expose the femoral shaft by blunt dissection between the lateral vastus muscle 
and the femoral biceps muscle. Using the distal screw as a pivot, the plate was diverted from the 
femur and a 1 mm non-critical midshaft full-thickness defect was created after a localized periosteal 
elevation with an electric circular saw under continuous sterile saline irrigation (Figure 1A). A 
compression stainless steel four-hole-mini-plate (length 20 mm, width 4 mm, height 1 mm) (Mini 
Fragment plate) was fixed on the anterolateral surface of the femoral diaphysis using four 1.5 mm 
Ø bicortical screws (all from Zimmer, Germany). In the infected groups, a volume of 30 µl of the 
bacterial suspension, corresponding to an inoculum of about 1x103, 1x105 and 1x108 CFU/rat was 
injected into the femoral defect and the suspension was allowed to spread throughout the medullary 
canal. The sham-inoculated control group received an inoculum of 30 µl sterile PBS. Then the 
muscular planes were closed with a continuous suture with Vycril 4/0 and the skin with separated 
stitches with Prolene 4/0 (Johnson&Johnson, Italy). The stability of the fracture was firstly 
manually assessed, then confirmed by fluoroscopic examination (Figure 1B). Atipamezole (1 
mg/kg; Antisedan, Pfizer) was administered subcutaneously to recover the animals from general 
anesthesia.  
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Figure 1. Plate positioning and postoperative analysis. (A) Plate diversion from the femur and the 
creation of a 1 mm non-critical midshaft full-thickness defect. The anatomical sites are reported as knee 
(K) and hip (H) joints. (B) Fluoroscopic examination of the femoral fracture and the correct plate 
position. The fracture of the femoral midshaft is shown by a black arrow. 
 
The animals were then housed in separate cages under an infrared lamp and monitored until the 
effects of anesthesia had worn off. About 24 hours later, animals were couple caged, monitored 
daily for general status and welfare, clinical signs of infection, lameness, weight bearing, swelling, 
local hyperemia, wound healing, serous exudate, hematoma, pain and suffering. The pain was 
controlled with buprenorphine (0.1 mg/kg SC; Temgesic, Schering Plough, Italy) immediately after 
surgery. After 8 weeks, the rats were euthanized by CO2 inhalation to perform the investigations. 
Anatomical dissection was performed under a laminar flow hood and in sterile conditions; the soft 
tissues were inspected for gross appearance, then stripped off the cortical bone surface, and the 
femurs were aseptically retrieved. 
 
Animal weight and blood analyses 
The body weight was measured in all animals at day 0 (day of operation) and weekly until the 
explantation. As an indicator of infection, hematology for each rat was performed on blood samples. 
Blood samples were collected from the tail vein on day 0 and day 14, and directly from the left 
ventricle immediately after sacrifice (day 56) to determine the peripheral neutrophil count, acting 
as first defenders against infections (n = 6 per group). The blood was promptly transferred to 
centrifuge tubes containing the appropriate anticoagulants for cell counting. Blood samples in 0.5 
M EDTA (Sigma Aldrich, Italy) were processed with an automatic cell counter (Sysmex XT-1800, 
Dasit, Italy) to obtain the white blood count and leukocyte formula. 
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Micro-CT imaging and data analysis 
Micro-CT imaging analysis was performed with an Explore Locus micro-CT scanner (GE 
Healthcare, Canada), without contrast agents. Immediately after sacrifice, the femurs (n = 6 per 
group) were removed, placed into a culture dish and scanned en bloc. A micro-CT lower-resolution 
(Bin-2) protocol was performed using 80kV voltage, 400 µA current with 400 msec exposure time 
per projection and 720 projections over 360° for a total scan time of approximately 24 minutes. The 
isotropic resolution of this protocol is 45 µm. The 3D reconstructed images were viewed and 
analyzed using the MicroView software (version 2.1.2; GE Healthcare). Individual micro-CT 
images were qualitatively scored for osteomyelitis by two blinded observers according to the 
Odekerken’s grading scale [28]: 0, no abnormalities; 1, mild periosteal reaction, cortical thickening; 
2, evident periosteal reaction, cortical thickening, and mild osteolysis; 3, extensive cortical 
thickening, cortical focal loss, evident osteolysis; 4, extensive cortical thickening, osteolysis, loss 
of cortical morphology. Bony bridging > 75% of the fracture gap was considered as healed fractures 
and bridging < 75% was seen as nonunion fracture, according to others [1]. Furthermore, a 
histogram-based isosurface rendering was performed on the fracture region. Then, after scan 
calibration, using a phantom made of an epoxy-based resin that mimics hydroxyapatite and contains 
water and air inclusion, a cylindrical volume of interest (VOI, 780 mm3) including the fracture site 
was designed between the proximal and distal screw to quantitatively measure the bone formation. 
The bone volume (BV, mm3) and tissue mineral density (TMD, mg/cc) were measured within the 
identified VOI as highest sensitive parameters in early stage of fracture healing [29].  
 
Microbiological analysis 
After 56 days, bacteria were recovered from samples (n = 5 per group) consisting in the plate, 
screws and peri-implant tissue. Samples were weighed and treated with dithiothreitol (DTT) to 
detach bacteria from the biofilm, as previously described [30]. Briefly, samples were immersed in 
a 0.1% w/v DTT (Sigma) solution in PBS and mechanically stirred for 15 min at RT. Samples were 
centrifuged and pellets suspended in 1 ml of the DTT eluate, 0.1 mL was then plated onto blood 
agar plates and inoculated in BHI broth. Plates were incubated for 48 hours at 37°C while incubation 
of broths at 37°C was prolonged for 15 days. Broths were daily checked for microbial growth. Then, 
10 µL from positive broths were plated onto blood agar plates which were incubated for 24 at 37°C. 
Gram-positive stained colonies were assessed for catalase test and for growth on Mannitol salt agar. 
Mannitol negative, coagulase negative, white, smooth, not hemolytic colonies on blood agar, 
resembling S. epidermidis were identified by pyrosequencing and counted. The (Log CFU)/g 
explant was determined by dividing the CFU number by the initial total weight of the sample. The 
limit of detection was set at 1 (Log CFU)/g. Phenotypic characteristics (biochemical and antibiotic 
susceptibility profiles) and sequences obtained by pyrosequencing were also compared with that of 
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the in vivo injected S. epidermidis to confirm strain identity. 
 
Histological analysis 
Femoral specimens (n = 5 per group) were fixed in 10% formalin for 24 hours. The bones were 
decalcified in Osteodec (Bio-Optica, Italy) for 7 days and dehydrated in alcohol scale before 
embedding the specimens in paraffin and cutting into 5 µm longitudinal sections. The slides were 
stained with haematoxylin and eosin (H&E) to assess morphology and with Gram staining for 
bacterial examination. Photomicrographs were captured using an Olympus IX71 light microscope 
and an Olympus XC10 camera (Japan). The samples were evaluated by two blinded observers to 
assess the percentage of the fracture healing and signs of osteomyelitis according to a grading score 
proposed in our previous study [31]. The Gram-positive staining was evaluated as present or absent.  
 
Scanning Electron Microscopy analysis 
After explantation, one sample per group was fixed in 2.5 % paraformaldehyde and 2.5 % 
glutaraldehyde in 0.1 M Na-Cacodylate buffer (pH 7.4; all from Sigma) for 24 hours. After fixation, 
the samples were fixed for 1 hour in 1 % osmium tetroxide (Sigma) in 0.1 M Cacodylate buffer, 
then prepared to expose the plate surfaces and dehydrated in ethanol scale, mounted on aluminum 
stubs and sputter-coated with gold using a SEMPREP 2 Sputter Coater (Nanotech Ltd, UK). 
Observations were performed with a LEO 1400 EVO Scanning Electron Microscope (Zeiss, 
Germany) mixing secondary and backscattered electrons detectors. Images were acquired at 10kV 
at a working distance of 7 mm. 
 
Statistical analysis 
The normal distribution of data was ascertained with the Shapiro-Wilk test. Comparisons among 
groups and time points were analyzed with two-way analysis of variance (ANOVA) (GraphPad 
Prism v5.00 Software, USA) coupled with Bonferroni’s post hoc test. Comparisons among groups 
were analyzed with one-way ANOVA corrected with Dunnett’s post hoc test. The interrater 
reliability of the examiners’ scores for micro-CT and histology were calculated with intraclass 
correlation coefficient (ICC): ICC = 1, perfect reliability; ICC > 0.75, excellent reliability. All data 
are expressed as means ± standard error (SE), unless specified otherwise. Values of P<0.05 were 
considered statistically significant. 
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Results 
 
In vitro antibiotic susceptibility and biofilm production  
The strain of S. epidermidis used in our infected non-union model was susceptible to gentamicin, 
vancomycin and fusidic acid (MIC ≤ 0.5 µg/ml), erythromycin and daptomycin (MIC ≤ 0.25 µg/ml), 
clindamycin and tigecycline (MIC ≤ 0.12 µg/ml), linezolid and tetracycline (MIC ≤ 1 µg/ml), 
teicoplanin (MIC = 4 µg/ml), trimethoprim/sulfamethoxazole (MIC ≤ 10 µg/ml). The strain was 
resistant to benzylpenicillin (MIC ≥ 0.5 µg/ml), oxacillin, cefazolin, rifampicin and levofloxacin 
(MIC ≥ 4 µg/ml). Based on the OD value (ODs vs ODc ratio: 6.38), the isolated strain was classified 
as a strong biofilm producer.  
 
Clinical examination 
During the follow-up period, none of the animals included in any group died or had clinical 
evidence of implant or systemic infection, such as local signs of peri-implant inflammation 
(hyperemia or exudation), diarrhea and behavioral alterations.  
At day 0 and weekly, the body weight (b.w.) was determined and reported as numerical data for all 
groups (Figure 2A). During the acute phase (7 days after surgery), infection induced anorexia 
associated with a b.w. loss in all infected groups, particularly in the 108 MRSE group compared to 
the control group (P<0.01). At the same time point, no b.w. loss occurred in the control group. 
Thereafter, in the control group, b.w. recovered progressively consistent with the standard Wistar 
rat-growing curve from day 14 until the end of the experiment. On the contrary, infected animals 
showed a less marked b.w. recovery during the same period; in particular, infected rats of the 108 
MRSE group recovered less b.w. than other infected groups from day 14 to day 35 after infection. 
A significant difference was found in the 108 MRSE group compared to the controls at different 
time points (P<0.001 at 14, 28 and 56 days; P<0.01 at 21, 35, 42 and 49 days). Unexpectedly, after 
35 days, the 108 MRSE group showed a sensible b.w. regain reaching values similar to the 103 
MRSE group. Conversely, the 105 MRSE group showed a permanent slow recovery of b.w. 
compared to other infected groups as well as to the control group with a significant difference at 
different time points (P<0.0001 at 35, 42, 49 and 56 days; P<0.01 at 14 and 28 days; P<0.05 at 21 
days). 
 
Blood laboratory tests 
The peripheral neutrophil count is reported as number of neutrophils x103/µl compared to the 
baseline (day of surgery, day 0) at 14 and 56 days after surgery (Figure 2B). Two weeks after 
infection, all animals exhibited an increase of the neutrophil count with respect to the basal values. 
In particular, both the 105 and 108 MRSE groups showed a significant increase of neutrophils 
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compared to the basal values (P<0.01 and P<0.001, respectively) and compared to the control group 
(P<0.05 and P<0.001, respectively). A significant difference in neutrophil count was also found in 
the 108 MRSE group compared with the 103 MRSE group at two-weeks post-operatively (P<0.01). 
Interestingly, the post-operative neutrophil count of the 103 MRSE group did not significantly differ 
from both the pre-operative basal values and from the control group at any time. In all groups, the 
peripheral neutrophil count almost normalized after eight weeks without showing any significant 
differences compared to the baseline. Interestingly, the 108 MRSE group showed the most 
significant decrease also compared to the same group at 2 weeks (P<0.001). No significant 
differences were detected among the experimental groups at 8 weeks.  
 
 
Figure 2. Clinical data. (A) The graph shows the numerical values of body weight (g) in the experimental 
groups over time. (B) The histogram shows the neutrophil count among experimental groups at day 14 and 
56 after surgery. The dotted line represents the baseline at day 0 before surgery. Comparisons between groups 
and time points were analyzed with two-way ANOVA and Bonferroni’s post-hoc. Statistical significance was 
P<0.05 (*, a, b), P<0.01 (**) and P<0.001 (***), n = 6.  
 
Imaging diagnosis 
The micro-CT qualitative analysis showed no signs of osteomyelitis in the control group in all the 
analyzed planes (Figure 3A, sagittal, coronal, and axial). Some animals displayed a restricted 
cortical bone reaction, whereas a well-organized bone callus, remodeling, and a good bone 
encapsulation of the screws were present in all cases. One sample of the control group was not 
evaluated due to the mechanical loss of the proximal screws followed by a fracture dislocation 
because of a surgical inaccuracy. Thus, this subject was excluded from quantitative analyses and 
dedicated to SEM investigation. All valuable samples (100%) showed a fracture healing > 75% 
with mineralized cortices and bony bridging across the medullary canal (Figure 3B). 
The 103 MRSE group displayed variable response to bacterial infection. The 67% of samples 
showed signs of altered bone healing. In particular, they exhibited both a diffuse cortical bone 
thickening associated with focal loss of the cortical wall and mild osteolysis around the screws near 
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to the fracture site (Figure 3C, sagittal, coronal, and axial). The fracture healing was < 75% and 
displayed mainly fibrous non-union (Figure 3D). 
The 105 MRSE group presented extensive signs of osteomyelitis both near the fracture site and 
extending to the metaphysis regions associated with severe osteolysis around the screws and 
resorption of the cortex, with a quite complete disruption of the bone integrity (Figure 3E, sagittal, 
coronal, and axial). Moreover, most of the samples demonstrated the presence of subcortical 
abscesses (Figure 3E, axial). The 83% of the samples showed a fracture healing < 75%, with 
absence of bony bridging, frequently associated with deformity of the femoral diaphysis (Figure 
3F). One animal showed no signs of osteomyelitis and a fracture healing around 75%.  
The 108 MRSE group showed extensive cortical thickening, severe periosteal reaction, loss of 
cortical wall and severe osteolysis around the screws near to the fracture site (Figure 3G, sagittal, 
coronal, and axial). All samples (100%) showed a fracture healing < 75%, and displayed nonunion 
extended across the entire bone (Figure 3H). 
 
 
Figure 3. Qualitative micro-CT imaging and isosurface. The representative panel shows micro-CT images 
on the day of explantation. The sagittal, coronal and axial planes (A, C, E, G), as well as a three-dimensional 
isosurface reconstruction (B, D, F, H) were presented for the control (CTRL), and the 103, 105, and 108 
MRSE groups. Symbols indicate: cortical reaction (white arrows); loss of cortical wall and osteolysis (yellow 
arrows); peri-implant osteolysis («); presence of abscesses (white circle).  
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Assessing the percentage of bony bridging, no significant difference was measured between the 103 
MRSE group and the control group or the105 and 108 MRSE groups, as well as between the 105 and 
108 MRSE group. The control group significantly differed from the 105 and 108 MRSE groups for 
P<0.05 and P<0.01, respectively. 
The interrater reliability of blind scoring based on the Odekerken’s scale was excellent—ICC 0.83 
(95% CI 0.51, 0.94)—and highlighted a significant higher osteomyelitis grade in the 105 and 108 
MRSE groups, but not for the 103 MRSE group, compared to the controls (P<0.05) (Figure 4A). 
The quantifications of BV and TMD were reported as percentage of decrease with respect to the 
control group in which, despite no significant difference was found, a lower BV was measured for 
all the infected groups with a higher trend in the 105 MRSE group (Figure 4B) as well as for the 
TMD with the exception of the 108 MRSE group (Figure 4C). 
 
 
Figure 4. Micro-CT-based semiquantitative and quantitative analyses of bone structure. (A) 
Osteomyelitis grading score based on Odekerken’s scale. (B) Bone volume (BV) quantitative analysis of the 
infected groups normalized on the control group, reported as a percentage. (C) Tissue mineral density (TMD) 
quantitative analysis of the infected groups normalized on the control group, reported as a percentage. 
Comparisons among groups were analyzed by one-way ANOVA. Statistical significance for P<0.05 (*), n = 
6. 
 
Microbiological tests 
No bacterial growth was observed in the control group (non-detectable values, n.d., L.o.D.). There 
was not a significant difference between the control group (n.d.) and the 103 MRSE group (1.5±1 
CFU/g explant, mean ± standard deviation), in which bacteria were found in three animals out of 
five. Considerable bacterial counts were found in samples of the 105 and 108 MRSE groups 
(10.33±9.5 and 20.33±27.4 CFU/g explant, respectively) with a significant difference compared to 
the control group (P<0.05 and P<0.01, respectively), as well as between the 103 and 108 MRSE 
groups a difference was measured (P<0.05). No significant differences in DNA sequences between 
strains isolated from animal explants and the parental strain were observed. In particular, all the 
isolated bacteria from rat explants were susceptible to gentamicin, vancomycin and fusidic acid 
(MIC ≤ 0.5 µg/ml), erythromycin and daptomycin (MIC ≤ 0.25 µg/ml), clindamycin and tigecycline 
(MIC ≤ 0.12 µg/ml), linezolid and tetracycline (MIC ≤ 1 µg/ml), teicoplanin (MIC = 4 µg/ml), 
trimethoprim/sulfamethoxazole (MIC ≤ 10 µg/ml) while they were resistant to benzylpenicillin 
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(MIC ≥ 0.5 µg/ml), oxacillin, cefazolin, rifampicin and levofloxacin (MIC ≥ 4 µg/ml). As far as 
biofilm production was concerned, all the isolated bacteria were classified as strong biofilm 
producers as well as the parental strain, without significant differences among 103, 105 and 108 CFU 
inoculum groups, as reported in Table 1. 
 
Table 1. Biofilm production of S. epidermidis isolated from the infected rats (ODs vs ODc ratio).  
Groups  Explants 
 A B C D E 
103 6.26 6.37 n.d. 6.47 n.d. 
105 6.28 6.58 5.67 6.54 6.14 
108 6.53 6.48 5.78 6.28. 6.21 
n.d. = non detectable 
 
Histological analysis 
The histological analysis confirmed the results obtained by micro-CT scans in terms of percentage 
of fracture healing and bone structure in the control group (Figure 5A). Specifically, fractures 
appeared closed with a great amount of new bone formation in a remodeling phase, sometimes 
associated with a mild cortical thickening (woven bone) (Figure 5B, upper box). The small portion 
of unclosed fracture displayed a well-organized fibrocartilaginous tissue (Figure 5B, lower box). 
No signs of osteomyelitis were detected as also displayed by the absence of bacteria reported by 
the Gram-positive staining. As aforementioned, animals of the 103 MRSE group showed a variable 
response to bacterial infection. Animals with a microbiological detectable infection showed an 
incomplete bone healing (Figure 5C) characterized by a great formation of fibrovascular tissue 
disseminated with scarce inflammatory cells (Figure 5D, upper box) and only sporadically replaced 
by cartilaginous tissue (Figure 5D, lower box). The cortices appeared uniformly enlarged with few 
areas of bone remodeling. Gram staining detected areas disseminated with Gram-positive cocci. 
Differently, infected rats, in which no bacteria were microbiologically retrieved, showed 
histological features resembling the findings of the control group. The 105 MRSE group showed a 
complete disorganization of the bone structure, the missing of cortical bridging with non-union 
establishment (Figure 5E). Severe signs of osteomyelitis were found: extensive periosteal reaction, 
cortical thickening, myeloid hyperplasia, a diffuse presence of polymorphonuclear cells in the 
granulation tissue (Figure 5F, upper box), multiple subperiosteal, intracortical and medullary 
abscesses and hematomas, and bone sequestra (Figure 5F, lower box). The severe osteomyelitis 
was also sustained by the presence of gram-positive bacteria in the bone and granulation tissue.  
The histology of the 108 MRSE group confirmed the results obtained by micro-CT scans. The 
analysis depicted a great deposition of fibrovascular tissue permeating from the cortical margin to 
the medullary canal, surrounding screws and embedding numerous polymorphonuclear cells 
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(Figure 5G). The severe osteomyelitis led to a massive cortical and endosteal osteolysis (Figure 5H, 
upper box). Subperiosteal sequestra were found together with a moderate periosteal reaction (Figure 
5H, lower box). Gram staining identified a massive presence of bacteria both intraosseous and 
within the periosteal and subperiosteal area.  
 
 
 
Figure 5. Histological analysis at the day of explantation. The representative panel shows H&E and Gram 
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staining in the four groups. The panels depict an overview of the samples, magnification 2x, scale bar 1000 
μm (A, C, E, G). The panels depict areas of interest of the black boxes, magnification 10x, scale bar 200 μm 
(B, D, F, H). The Gram staining depicts bacterial colonies identified by the white boxes, magnification 4x, 
scale bar 500μm and specific regions within the small boxes, magnification 40x, scale bar 50 μm. Bo, bone; 
Fc, fibrocartilaginous callus; Fv, fibrovascular tissue; Ab, abscesses  
 
The interrater reliability of blind scoring based on the Petty’s scale was excellent—ICC 0.82 
showed no signs of bone infection and the 103 MRSE group displayed only a mild inflammatory 
reaction with particular reference to the cortex, as shown in Figure 6B. A moderate to severe 
osteomyelitis was found in the 105 and 108 MRSE groups with a significant difference with respect 
to the control group for P<0.01 and 0.05, respectively. Moreover, a significant difference was found 
in terms of periosteal reaction between the 103 MRSE group and both the 105 and 108 MRSE groups 
for P<0.001 and P<0.01, respectively.  
  
Figure 6. Histological score based on Petty’s scale. The histogram compares the semiquantitative score 
performed on the periosteum, cortex and medullary canal regarding the osteomyelitis signs. (A) Total score 
analysis. (B) Fold increase of the grading scale of the infected groups with respect to the control group. 
Comparisons among groups were analyzed by one-way ANOVA. Statistical significance for P<0.05 (*), 
P<0.01 (**), P<0.001 (***), n = 5.  
 
Scanning electron microscopy analysis 
The control group without S. epidermidis contamination was completely free from biofilm 
formation on the surface of the implanted stainless-steel plate both on its top (Figure 7A) and 
bottom side (Figure 7B), where the presence of bony bridging on the bone-implant interface was 
detected (Figure 7B, small box). A little presence of free cocci, ranging from 1–2 µm of diameter, 
was detected on the plate surface in the 103 MRSE group, in which a scarce mucoid material 
occasionally coated cocci (Figure 7C and 7D).  
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Figure 7. Representative photographs of SEM analysis of biofilm formation. Absence of biofilm 
formation in the control group either on the top (A) or on the bottom (B) of the implanted plate (magnification 
40x, scale bar 1mm) with the presence of bony bridging structure on the bone-implant interface (B small box, 
magnification 6700x, scale bar 2μm). Presence of few coccidal bacteria on the top of the plate (C, D, 
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magnifications 40x and 250x, scale bars 1mm and 200μm, respectively) occasionally coated with mucoid 
material in the 103MRSE group (D small box, magnification 3000x scale bar 10μm). Presence of cocci within 
the peri-implant fibrous tissues covering the plate and on the top of the plate (E, magnification 40x, scale bar 
1mm), free or partially embedded into mucous-gelatinous matrix in the 105MRSE group (F, magnification 
70x, scale bar 200μm; F small box, magnification 3000x scale bar 10μm). Clusters of cocci adhering to the 
top of the plate surface (G, H, magnifications 40x and 90x, scale bars 1mm and 200μm, respectively) 
completely embedded in a well- organized biofilm matrix in the 108MRSE group (H small box, magnification 
3000x, scale bar 10μm).  
 
Differently, in the 105 MRSE group, bacteria were mainly present on the plate surface and within 
the peri-implantar fibrous tissues covering the plate, free or partially embedded into mucous-
gelatinous matrix (Figure 7E and 7F). As expected, in the 108 MRSE group, several clusters of 
cocci were identified adherent at the top and bottom of the plate surface (Figure 7G and 7H) 
completely embedded in a well-organized and three-dimensional self-produced extracellular 
polymer structure, the biofilm, able to entrap also platelets, erythrocytes and polymorphonucleated 
cells (Figure 7H, small box).  
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Discussion 
 
Postoperative infections and invasive trauma causing septic non-union are still a major clinical 
problem that requires specific preclinical models. An interesting model has been proposed by Chen 
and colleagues [17] combining a critical bone defect in the rat femur with a local injection of S. 
aureus. This model may not effectively characterize the clinical condition in which septic non-
unions develop. Actually, critical bone defects do not heal spontaneously, thus in vivo non-union 
models should avoid the combination of critical defect and bacterial inoculation to better understand 
the pathogenesis of infection in fractures, as also suggested by others [32, 33]. In our study, we 
proposed a standardized osteotomy model devoid of a critical bone defect associated with a local 
infection. This approach aims to better understand the role of bacteria in the non-union development 
with particular reference to subclinical contaminations and to generate a useful preclinical model 
of non-union-related infection for future therapeutic approaches. Similarly, Alt and colleagues [1] 
established a model of S. aureus non-unions of the tibia after intramedullary fixation. To resemble 
human procedures for complicated femoral fractures, we provided a direct fracture fixation with 
plates, we used a pathogen commonly involved in implant colonization and we administered routine 
antimicrobial prophylaxis. S. epidermidis biofilm formation is a well-known virulence factor in the 
development of implant infection [34]. Thus, to better recreate a human clinical setting, we 
developed a model taking advantage of a prosthetic-derived MRSE-strain selected for its ability to 
produce biofilm. The antibiotic susceptibility of the selected MRSE-strain was comparable to that 
of collection numbered ATCC35984, particularly referred to daptomycin and vancomycin [18]. 
Despite similar antibiotic susceptibility to ATCC35984, MIC values for vancomycin and 
daptomycin of our clinical strain were lower than the referenced one [18]. 
Moreover, we treated animals with a preoperative systemic, broad-spectrum cephalosporin 
(cefazolin), since it is considered the first choice in orthopaedic prophylaxis according to the 
specific guidelines [35]. Thus, we tried to prevent other than MRSE contaminations by using 
cefazolin to have a deeper insight in this specific bacterial infection. Again, male animals were 
selected to avoid the influence of hormonal cycles on bone repair and turnover, as also suggested 
by others [33]. In the literature scenario, there are several studies on osteomyelitis or septic arthritis 
animal models, but few studies report models of infections during the fracture healing by employing 
S. aureus as main strain [1,16, 17, 36–38]. Differently, we proposed a dose-dependent S. 
epidermidis-induced non-union model, belonging S. epidermidis to the normal skin flora and being 
responsible for most of the metal implant infections [13, 39]. To our best knowledge, there are not 
currently animal models simulating a S. epidermidis-related nonunion of the femur after internal 
plate stabilization. In fact, only few studies describe the MRSE-related orthopaedic infections 
mainly focused on prosthetic joint infection [22] or intramedullary osteomyelitis [24]. 
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In our results, the changes in b.w. and neutrophil count were correlated with the host response to 
infection. The b.w. loss reflected the dose-dependent trend in the infected rats, as well as the 
increase of the neutrophils during the acute phase of infection. Overall, most of the analyses 
highlighted a worse condition in the 105 MRSE group compared to the others. The recovery of the 
108 MRSE group in terms of both b.w. and the systemic neutrophil count could be related to the 
capability of the formed biofilm to locally attract activated neutrophils reducing their presence in 
the circulating blood. This finding was histologically supported by the abundant presence of local 
polymorphonuclear cells and severe host tissue damages. Hence, this suggested a quicker, stronger 
and mature biofilm formation induced by the higher dose of injected bacteria (108 MRSE) with 
respect to the other infected groups, as demonstrated by Gram staining, microbiological and SEM 
analyses. Thus, the greater amount of biofilm with a high mechanical stability allowed bacteria to 
escape from neutrophil assault. This supported the low susceptibility to phagocytic destruction by 
neutrophils of the S. epidermidis [40]. The inability to kill bacteria associated with a great amount 
of protective biofilm slowed the cocci metabolic rate leading to a chronic osteomyelitis 
development and eventually delaying the fracture bone healing [13]. S. epidermidis autolysin (AltE) 
has been suggested to mediate the primary attachment to the implant surface and to bind vitronectin, 
an abundant glycoprotein found in serum, extracellular matrix and bone, promoting cocci spreading 
[41]. The autolysin/adhesin system binds fibrinogen, fibronectin, and vitronectin in a bacterial dose-
dependent fashion [41], explaining the greater amount of biofilm formation in the 108 MRSE group 
compared to the 105 MRSE one. Moreover, S. epidermidis embedded in biofilm commonly 
produces quorum-sensing controlled virulence factors as the one encoded by the accessory gene 
regulator (agr) system. In addition, the transcription of Agr gene is also induced by the presence of 
neutrophils and regulates biofilm formation in S. epidermidis by acting on AtlE and toxin 
expression that cause a rapid lysis of local polymorphonuclear cells [10, 42]. Therefore, the vicious 
circle of neutrophils promoted the biofilm formation and aggravated the local inflammatory 
response. Although S. epidermidis has a lower pathogenic potential, most staphylococcal infections 
are chronic especially in patients with associated predisposing factors such as diabetes or peripheral 
vascular disease, as we have previously demonstrated [31]. 
Differently, the 105 MRSE group showed a more severe condition in terms of osteomyelitis signs 
and non-union establishment, as properly supported by micro-CT and histological analysis, despite 
a lower detection of bacterial growth. In this group, subacute osteomyelitis was characterized by 
abscesses at the site of bacterial colonization frequently associated with vascular and bone damages, 
like cortical resorption and sequestra. Sequestra represent foci of recurrent infection that could lead 
to the chronic osteomyelitis development over time. Accordingly, in these rats, the subacute 
infection was also related to a higher symptomatic status in terms of b.w. decrease and circulating 
neutrophils, as also supported by others [43]. Reducing the bacterial load and consequently the 
biofilm production in the 105 MRSE respect to the 108 MRSE group could be responsible of a higher 
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presence of free cocci in the fracture site. In fact, this lower microbial dose induced a subacute host 
response fighting against cocci, with both maintenance of high levels of circulating neutrophils and 
local cellular immune reaction (abscess formation). This phenomenon could be reasonably 
controlled by using appropriate antimicrobial treatment for MRSE, considering that bacteria in such 
specific case are poorly embedded in a weak and immature extracellular matrix. More interestingly, 
the 103 MRSE group displayed an inconsistent grade of infection and fracture healing. This could 
be related to the specific host immune system that was able to spontaneously eradicate the infection 
determined by a low-grade of MRSE injection in 33% of rats, as demonstrated also by other authors 
[28]. According to our experience, this group showed subclinical features of infected fractures, in 
which the bone repair or damages are filtered by the host immune defense and bacteria did not 
trigger signs or symptoms of a post-surgical infection. Findings of our study, in which a low grade 
of S. epidermidis administration in the presence of metal implants seems to be a good model for 
subclinical perioperative infections, are consistent with those supported by Qin and colleagues in 
an implant-related osteomyelitis in a rat model [24]. The spontaneous eradication of infection 
occurred in some cases of the 103 MRSE group suggests the inadequacy of low grade infection in 
creating a reliable and reproducible model of infected non-unions, supporting another study on S. 
epidermidis graft infections [44]. Conversely, it may represent a useful approach to have a deeper 
insight of the subclinical event in terms of pathogens and host response.  
The control group was free of clinical and diagnostic signs of infection and showed a quite complete 
fracture healing, as expected. The restrict cortical bone reaction detected by micro-CT is due to the 
periosteal elevation performed during surgery to properly create the fracture by means of a circular 
saw. According to some authors, the cautery-induced periosteal damage induced an atrophic 
nonunion [45]. In our study, we carried out a simple periosteal cut and elevation without provoking 
necrotic damages. This variability was adopted in all animal groups. In the development of our 
models, some limitations were encountered in the micro-CT imaging related to the scattering 
artifacts of the stainless-steel plates and screws. This phenomenon was particularly limiting for the 
quantitative analyses. To overcome this limit, the use of titanium implants could be helpful to 
reduce scattering artifacts and to apply validated protocols for micro-CT acquisition. Anyway, 
thanks to the combination of several diagnostic techniques, our bone analysis provided adequate 
information on fracture healing and osteomyelitis associated to microbial infections. Our modeling 
is reliable for the assessment of osteomyelitis and fracture healing, offering a good correlation of 
their typical features. Moreover, the small number of animals included in this research could be 
also considered a limitation, despite offering an innovative and interesting preclinical model. 
Indeed, at this writing, there are not available rodent models describing the use of S. epidermidis to 
determine an orthopaedic infection associated with non-union fractures. This is also the first time 
that the impact of bacterial load has been investigated with regard to bone healing after fracture and 
osteosynthesis and that the effect on bone healing of a subclinical infection due to S. epidermidis 
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contamination of a metallic plate is shown. Although this research is a pilot study, the model 
appears both as a more traditional tool, designed to study implant-related infections due to a 
common pathogen, like S. epidermidis, and as a more innovative way to investigate the 
underestimated effect of subclinical contamination of bone due to trauma or surgery.  
 
 
Conclusions 
 
Our models of subclinical and evident orthopaedic infection constitute clinically relevant tools for 
studying prophylactic and therapeutic strategies or biofilm pathogenesis in infected nonunion 
establishment as well as models for the assessment of sophisticated diagnostic approaches. 
Importantly, our modeling could be used in the next feature to characterize by proteomics the 
adaptation and changes of bacteria during the different stages of the infective process and biofilm 
formation. 
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Abstract 
 
This study compares the response to S. epidermidis-infected fractures in rats systemically or locally 
injected with vancomycin or bone marrow mesenchymal stem cells (BMSCs) in preventing the 
nonunion establishment. The 50% of rats receiving BMSCs intravenously (s-rBMSCs) died after 
treatment. A higher cytokine trend was measured in BMSCs locally injected rats (l-rBMSCs) at day 
3 and in vancomycin systemically injected rats (l-VANC) at day 7 compared to the other groups. 
At day 14, the highest cytokine values were measured in l-VANC and in l-rBMSCs for IL-10. Micro-CT showed a good bony bridging in s-VANC and excellent both in l-VANC and in l-
rBMSCs. The bacterial growth was lower in s- VANC and l-VANC than in l-rBMSCs. Histology 
demonstrated the presence of new woven bone in s-VANC and a more mature bony bridging was 
found in l-VANC. The l-rBMSCs showed a poor bony bridging of fibrovascular tissue. Our results 
could suggest the synergic use of systemic and local injection of vancomycin as an effective 
treatment to prevent septic nonunions. This study cannot sustain the systemic injection of BMSCs 
due to high risks, while a deeper insight into local BMSCs immunomodulatory effects is mandatory 
before developing cell therapies in clinics. 
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Introduction 
 
Open fractures are notorious to be at high risk of bacterial contaminations, mainly supported by the 
osteosynthesis devices that induce the biofilm development and a delayed bone healing [1]. S. 
epidermidis is one of the most involved pathogens in bone infections and nonunions [2] creating a 
protective niche from antimicrobial treatments [3]. At present, the standard therapy for orthopaedic 
infections implicates the systemic administration of antibiotics [4]. However, the long-term use of 
antibiotics, insufficient to reach bacteria within the biofilm matrix, generates a multidrug resistance 
leading to methicillin-resistant S. epidermidis (MRSE) [5]. Moreover, the antibiotic prophylaxis 
could be inadequate in case of fractures associated with vascular injuries, which reduce the local 
drug concentration. Hence, alternative prophylaxis strategies need to be assessed not only to prevent 
bacterial infections but also to support the bone repair. Many antimicrobial agents have been 
incorporated into biomaterials to be locally delivered [6]. Specifically, a novel bioresorbable 
hydrogel was in vitro and in vivo validated as an orthopaedic implant coating and antibiotic slow-
releasing delivery to impair the bacterial colonization through an antimicrobial competitive 
inhibition [7-9]. Nowadays, cell therapies have also been proposed to promote the bone repair [10]. 
Mesenchymal stem cells (MSCs) are claimed to be one of the most frequently used cell types thanks 
to their high proliferative ability and easy accessibility. MSCs have unique immunologic features 
that support their viability and proliferation in nonself environments [11]. The use of allogeneic 
MSCs may drastically reduce the waiting time to obtain a relevant cell amount for clinical use [12], 
as supported by orthopaedic clinical trials (ClinicalTrial.gov #NCT02307435 and #NCT01586312). 
Furthermore, MSCs ability to restrain bacterial infections has been hypothesized having both 
proangiogenic and immunomodulatory characteristics that promote the release of mediators 
(cytokines and chemokines) [13, 14]. In a recent study, we provided evidence of dose-dependent 
MRSE-induced nonunions in rats [15], demonstrating that subclinical orthopaedic infections are 
diagnosed with a significant delay. Typically, in clinics, the C reactive protein remains the most 
used biomarker of infection, despite a scarce sensitivity and specificity [16]. To supportmedical 
treatments for infections, identifying reliable predictive markers is urgency. Cytokines play an 
important role during the host response to infections inflammation and tissue repair by recruiting 
the cell mediated immunity, before any clinical appearance [17]. Importantly, the inflammation 
associated with fractures induces a precocious cytokine release that is essential during the early 
stage of bone healing [18]. However, a prolonged release of inflammatory cytokines fails to 
stimulate the osteogenic differentiation of resident MSCs recruited on the fracture site leading to 
an impaired healing [18], and the presence of bacteria highly influences the inflammatory cytokines 
and bone healing. In the present study, we compare the host response to MRSE-related infections 
of femoral fractures in rats treated with cell therapies, conventional systemic antibiotic prophylaxis, 
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and antibacterial-coated implant devices. We hypothesize that transplanted MSCs in a nonunion rat 
model could have benefits on bone healing and prevention of septic nonunion development thanks 
to MSC immuonomodulatory effects. Moreover, we hypothesize a role of circulating cytokines in 
the MRSE-related infections presuming a different activity, according to the received treatments. 
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Materials and Methods 
 
Study Design and Procedures 
This study on animals was approved by the Mario Negri Institute for Pharmacological Research 
(IRFMN) Animal Care and Use Committee (IACUC) (Permit number 06/2014-PR).The IRFMN 
adheres to the principles set out in the following laws, regulations, andpolicies governing the care 
anduse of laboratory animals: Italian Governing Law (D.lgs 26/2014; Authorization number 
19/2008-A issued March 6, 2008, by Ministry of Health); Mario Negri Institutional Regulations 
and Policies providing internal authorization for persons conducting animal experiments (Quality 
Management System Certificate—UNI EN ISO 9001:2008—Reg. number 6121); the NIH Guide 
for the Care and Use of Laboratory Animals (2011 edition); and EU directives and guidelines (EEC 
Council Directive 2010/63/UE). TheStatement of Compliance (Assurance) with the Public Health 
Service (PHS) Policy on Human Care and Use of Laboratory Animals has been recently reviewed 
(9/9/2014) and will expire on September 30, 2019 (Animal Welfare Assurance #A5023-01).  
Thirty 12-week-old maleWistar rats (body weight 373.56 ± 24.82 g) (Harlan Laboratories SRL) 
were used in this study. Briefly, rats were maintained under general anesthesia and received a 
preoperative intramuscular single injection of cefazolin (30 mg/kg, Cefamezin, Teva) and a 
subcutaneous treatment with carprofen (5 mg/kg, Rimadyl, Pfizer). The rats were osteotomized on 
the right femur and the fracture was synthesized with stainless steel plate and bicortical screws (all 
from Zimmer®, Germany). All animals were injected into the femoral defect with an inoculum of 
1x105 CFU/30 µl of MRSE strain #GOI1153754-03-14, as validated and widely described in our 
previous study [15]. Briefly, to prepare the inoculum, a colony of the MRSE strain was cultured 
into Brain Heart Infusion Broth (BioMérieux) and incubated at 37°C for 16 hours. The bacterial 
pellet was suspended in sterile saline to obtain a 10 McFarland turbidity equal to about 3 x 109 
CFU/ml; then the bacterial suspension was diluted with sterile saline solution to obtain a bacterial 
load of 1 × 105 CFU/30 µl. The bacterial inocula were confirmed by agar plate counting procedures 
and stored at 4°C until use. After the bacterial inoculum, the muscular planes were closed with 
Polysorb 4/0 and the skin with Monosof 4/0 (Covidien).The rats were randomly divided into five 
groups (n = 6 each group): the positive control group (PC) did not receive any therapeutic treatment 
(Figure 1A); the systemically treated groups received intravenousl vancomycin (15 mg/kg, Hikma) 
(s-VANC) or allogeneic rat bone marrow MSCs (s-rBMSCs) immediately after surgery; the locally 
treated groups received a local injection of rBMSCs (l-rBMSCs) (Figure 1B) 24 hours after surgery 
or a local layering of a vancomycin-enriched hydrogel (l-VANC) (Figure 1C and 1D) during 
surgery. Atipamezole (1 mg/kg, Antisedan, Pfizer) was administered subcutaneously to recover rats 
from general anesthesia. The animals were monitored daily for general status and welfare, clinical 
signs of infection, lameness, weight bearing, swelling, local hyperemia, wound healing, serous 
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exudate, hematoma, pain, and suffering. The pain was controlled with buprenorphine (0.1mg/kg 
SC, Temgesic, Schering Plough, Italy) immediately after surgery. Three animals of the s-rBMSCs 
group died within 6–10 hours after surgery for respiratory complications. Their lungs and hearts 
were explanted and histologically analyzed. From here on, the investigations regarding the s-
rBMSCs group were performed on the remaining three animals. Overall, the animals were 
monitored for body weight changes, neutrophil counts, and circulating cytokines during the follow-
up period. After 6 weeks, rats were euthanized by CO2 and micro-CT scans; microbiological and 
histological analyses were performed to assess the bone healing and infection. 
 
  
Figure 1. Treatments in the experimental groups. (A) All animals received MRSE locally. The picture 
represents the injection of the bacterial suspension within the site of the fracture. (B) Representative picture 
of the local treatment with rBMSCs in the site of the fracture 24 h after surgery. e picture represents the 
transcutaneous injection of rBMSCs after disinfection within the site of the fracture. (C) e l-VANC group 
received a vancomycin-enriched hydrogel locally layered on the plate surface before the fracture stabilization 
and (D) within the site of the osteosynthesis after the plate fixation. e pictures represent the distribution of 
250 μl of the vancomycin-enriched hydrogel on the bottom (C) and top side of the plate (D).  
 
Culture and Preparation of Rat BMSCs 
Allogeneic Wistar rBMSCs (Oricell®, Cyagen Biosciences, Cat. Number RAWMX-01001, 
passage 2) were used. Cells were expanded in medium composed of 4.5 g/L glucose Dulbecco’s 
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Modified Eagle’s Medium, 100 U/mL penicillin-streptomycin, 2 mM L-glutamine, 1% sodium 
pyruvate, 1% HEPES (all from Gibco), and 10% fetal bovine serum (Hyclone). At passage 5, 
undifferentiated rBMSCs were differently injected in the rats at concentration of 2 x 106 cells/kg.  
 
Antimicrobial Coating Preparation 
A resorbable hydrogel called DAC (Defensive Antibacterial Coating, Novagenit Srl) was enriched 
with vancomycin at 5% (v/w), according to manufacturer’s guidelines and others [8], and then 
distributed on plates and screws during the osteosynthesis of the l-VANC group. Briefly, to prepare 
the vancomycinenriched hydrogel, 500 mg of vancomycin was diluted in 10 ml of sterile water, 
and then 5 ml of this suspension was used to solubilize the hydrogel, thus obtaining an enriched 
hydrogel containing 50 mg/ml of vancomycin. In the l-VANC group, plates and screws implanted 
were coated with 250 µl of enriched hydrogel, thus delivering locally 35 mg/kg of vancomycin. 
 
Body Weight and Blood Analyses 
The rat body weight was measured before surgery and weekly until the day of explantation (day 
42) and reported as relative b.w. increase on the baseline (day of surgery). On days 0, 14, and 42 (n 
= 6 per group; n = 3 s-rBMSCs), venous blood was harvested from the tail vein under general 
anesthesia and then transferred into K2 EDTA tubes (Microtainer MAP, Becton Dickinson) to 
determine the neutrophil count. On days 3, 7, and 14 after surgery, plasma was obtained by 
centrifuging the samples (n = 4 per group; n = 3 s-rBMSCs) at 1200 xg for 10min at RT and stored 
at −80∘C until use for the cytokine analysis (IL-1α/β, IL-6, IL-10, TNF-α, and IFN-γ) by means of 
the Luminex assay kit (Bio-Plex Pro® Rat Cytokine Assay, Bio-Rad) according to the 
manufacturer’s instructions. Measurement was performed in duplicate by using a Bio-Plex 200 
system based on the Luminex xMAP technology (Bio-Rad, Hercules). Cytokine levels are reported 
as pg/ml. 
 
Micro-CT Imaging 
The qualitative and quantitative micro-CT analyses on femurs were performed with an Explore 
Locus micro-CT scanner (GE Healthcare), as previously described elsewhere [15]. Bony bridging 
percentage of >75%, 50–75%, or <75% of the fracture gap was evaluated and scored. The bone 
volume (BV, mm3) and tissue mineral density (TMD, mg/cc) were calculated within the volume of 
interest, as described by others [19]. Data were reported as fold increase of the treated groups on 
the PC group. 
 
Microbiological Analysis 
After 42 days, bacteria were recovered from explanted femurs (n = 6 per group; n = 3 s-rBMSCs) 
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by treating samples with dithiothreitol to dislodge bacteria from the biofilm and analyzed as 
previously described [15, 20]. Data were reported as Log (CFU/g) explant. 
 
Histological Analysis 
Femurs (n = 6 per group; n = 3 srBMSCs) were fixed in 10% formalin, decalcified in Osteodec 
(Bio-Optica), embedded, and cut into 5 µm sections. Haematoxylin and eosin (H&E) staining was 
performed to assess morphology, fracture healing, and signs of osteomyelitis. The Gram-positive 
staining was evaluated for presence or absence of bacteria. Olympus IX71 light microscope and 
Olympus XC10 camera (Japan) were used to obtain images. 
 
Statistical Analysis 
After verifying the normal distribution of data with the Shapiro-Wilk test, comparisons among 
groups and time points were analyzed with two-way analysis of variance (ANOVA) and 
comparisons among groups were analyzed with one-way ANOVA (GraphPad Prism v5.00 
Software) and then coupled with Bonferroni’s post hoc test. All data are expressed as means ± 
standard error (SE). Values of 𝑝 < 0.05 were considered statistically significant. 
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Results 
 
Clinical Examination 
The histological analysis of the organs of the s-rBMSCs treated rats did not show any cardiac 
alteration but assessed the presence of acute hyperemia associated with multifocal alveolar edema 
and hemorrhage in the lungs (Figure 2). Despite emboli within pulmonary arteries were not evident, 
the interlobular septa were markedly inflated with fluid and diffuse diffuse congestion (Figure 2, 
asterisk), presence of macrophages and polymorphonucleated cells within the parenchyma 
indicating a severe inflammatory reaction. During the follow-up period, no other animals of any 
group died or presented peri-implant inflammation. From days 3 to 7, three PC rats showed a partial 
load bearing on the operated limb without any clinical evidence of infection. 
 
  
Figure 2. Representative histological panel of the rat lungs reporting the effects of the acute intravenous 
administration of allogeneic BMSCs in the s-rBMSCs group. The lung sections are stained with 
haematoxylin and eosin. (A, B) Presence of acute and diffuse hyperemia within the lung parenchyma. (C) 
Presence of multifocal alveolar edema (∗). (A) scale bar 1000 μm; (B) scale bar 200 μm; (C) scale bar 50 μm.  
 
Body Weight and Blood Analyses 
The relative b.w. increase on the baseline was represented in Figure 3(a). At day 7, a b.w. loss was 
recorded in all groups. At day 14, lrBMSCs and l-VANC showed a b.w. decrease and a slower b.w. 
recovery throughout the experimental follow-up compared to the other treated groups. Differently, 
s-VANC depicted a significant b.w. increase compared to l-VANC, l-rBMSCs, and PC over time. 
In Figure 3B, the neutrophil count is reported as number of neutrophils ×103/µl compared to the 
baseline (day 0). After 14 days, PC showed a significant neutrophil increase compared to the basal 
values and to l-VANC. After 42 days, the neutrophil count almost normalized in all groups without 
any significant differences compared to the basal values and among the experimental groups. 
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Figure 3. Clinical data. (A) e histogram shows the relative changes in body weight in the 
experimental groups over time. (B) e histogram shows the systemic neutrophil count in the 
experimental groups at days 14 and 42 after surgery. Comparisons between groups and time points 
were analyzed with two-way ANOVA and Bonferroni’s post hoc test. Statistical significance was 
p < 0.05 (∗),p < 0.01 (A, ∗∗), and p < 0.001 (#); n = 6, n = 3 s-rBMSCs.  
 
Pro- and Anti-Inflammatory Cytokines  
Plasma levels of pro inflammatory (IL-1a/b, TNF-a, and IFN-g), anti-inflammatory (IL-10), and 
regulatory (IL-6) cytokines were assessed at days 3, 7, and 14 (Figure 4). In most of the groups, all 
cytokines showed the same changes with time. Overall, at day 3, PC and l-rBMSCs had a higher 
cytokine trend with respect to the other groups. At day 7, PC and s-VANC showed a higher cytokine 
trend compared to the other groups. Similarly, this trend was found for IL-1b in s-rBMSCs, for IL-
10 in l-rBMSCs, and for IFN-g in l-VANC. At day 14, the highest cytokine values were measured 
in PC and l-VANC and just for IL-10 in the l-rBMSCs group. Particularly, PC had a higher trend 
for all the analyzed cytokines compared to the other groups at day3 and peaked at 7 days after 
injection. Moreover, PC demonstrated the highest cytokine activity compared to the treated groups. 
Mainly at day 7, PC had increased values of the acute phase cytokines (IL-1a/b and TNF-a) with 
significant differences compared to l-VANC, s-rBMSCs, and l-rBMSCs. This trend was found also 
on day 3 for TNF-a in the PC group. Moreover, s-VANC showed a higher trend compared to l-
VANC. Differently, the anti-inflammatory cytokines (IL-10) and the late phase (IFN-g and IL-6) 
did not show a significant difference in PC compared to all the treated groups. At day 3, l-rBMSCs 
showed higher values for IL-1a/b, TNF-a, and IFN-g with respect to s-VANC and l-VANC. At 
day 14, l-VANC showed a higher trend with respect to the other groups in all the analyzed 
cytokines, with a significant difference for TNF-a	and IL-6 with respect to s-VANC. 
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Figure 4. Cytokine analysis. The histograms show the cytokine values of the experimental groups at 3, 7, 
and 14 days after surgery and bacterial injection. Comparisons between groups and time points were analyzed 
with two-way ANOVA and Bonferroni’s post hoc test. Statistical significance was p < 0.05 (∗),p < 0.01 (∗∗), 
and p < 0.001 (∗∗∗); n = 4, n = 3 s-rBMSCs.  
 
Micro-CT Imaging Diagnosis 
The micro-CT qualitative analysis depicted a variable percentage of bony bridging in the 
experimental groups (Table 1). 
 
Table 1. Percentage of bony bridging of the fracture site.  
 Bony bridging 
 < 75% 50-75% > 75% 
 Nonunion fracture Partial fracture healing Fracture healing 
PC 83% (5/6) 17% (1/6) n.d. (0/6) 
s-VANC n.d. (0/6) 67% (4/6) 33% (2/6) 
l-VANC 33% (2/6) 17% (1/6) 50% (3/6) 
s-rBMSCs n.d. (0/6) n.d. (0/6) 100% (3/3) 
l-rBMSCs 33% (2/6) 17% (1/6) 50% (3/6) 
 
The osteomyelitis grading score for this group showed significant difference with respect to all the 
treated groups, while no significant differences were found between the treated groups (Figure 5K). 
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BV and TMD were reported as fold increase with respect to the PC group in Figure 6A and 6B. No 
significant differences were found for BV between the treated groups; differently, the fold increase 
of TMD was higher in s-rBMSCs with respect to both l-VANC and l-rBMSCs. 
 
Figure 5. Qualitative micro-CT imaging, isosurface, and semiquantitative osteomyelitis score. The 
representative panel shows micro-CT images on the day of explantation. (A, C, E, G, I) Sagittal, coronal, 
and axial planes. (B, D, F, H, J) 3D isosurface reconstruction is presented for the s-VANC, s- rBMSCs, l-
VANC, l-rBMSCs, and PC groups. Symbols indicate cortical reaction (white arrows); medullary reaction 
(yellow arrow); and loss of cortical wall and osteolysis (asterisks). (K) Osteomyelitis grading score based on 
Odekerken’s scale is reported in the histogram. Comparisons among groups were analyzed with one-way 
ANOVA corrected with Bonferroni’s post hoc test. Statistical significance was p < 0.05 (∗) and p < 0.001 
(∗∗∗); n = 6, n = 3 s-rBMSCs.  
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Figure 6: micro-CT quantitative analyses of bone structure. (A) Bone volume (BV) and (B) tissue mineral 
density (TMD) quantitative analysis of the treated groups normalized on the PC group, reported as fold 
increase. Comparisons among groups were analyzed with one-way ANOVA corrected with Bonferroni’s post 
hoc test. Statistical significance was p < 0.05 (∗) and p < 0.01 (∗∗); n = 6, n = 3 s-rBMSCs.  
 
Microbiological Analysis 
The microbiological analysis reported in Figure 7 detected a significant higher bacterial growth 
between PC and both s-VANC and l-VANC. Moreover, l-VANC showed a lower bacterial growth 
with respect to l-rBMSCs. The limit of detection was set at 0.18 Log (CFU/g) explant. 
 
Figure 7. Microbiological detection of bacterial growth on the explanted specimens. The limit of 
detection (L.o.D.) was set at 0.18 Log(CFU/g)/explant. Comparisons among groups were analyzed with one-
way ANOVA corrected with Bonferroni’s post hoc test. Statistical significance was p < 0.05 (∗),p < 0.01 
(∗∗), and p < 0.001 (∗∗∗); n = 6, n = 3 s-rBMSCs.  
 
Histological Analysis  
The H&E staining confirmed the results obtained by micro-CT in terms of percentage of fracture 
healing and absence of osteomyelitis in s-VANC, l-VANC, and s-rBMSCs (Figure 8).  
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Figure 8. Histological analysis (H&E) at the day of explantation. The representative panel shows H&E 
staining of the femurs in all the experimental groups. The panels depict an overview of the samples, scale bar 
1 mm. WB: woven bone; LB: lamellar bone; PR: periosteal reaction; FV: fibrovascular tissue; MH: myeloid 
hyperplasia; vascular infiltrates (black arrow); alteration of cortical bone (green arrow). For the l-rBMSCs 
group, (A) a specific area containing fibrovascular tissue and polymorphonucleated cells is reported in the 
big black box (scale bar 200 μm) and (B) the presence of giant cells in the small black box (scale bar 100 
μm) is reported. For the PC group, (C) a specific area with fibrovascular tissue is reported in the big red box 
(scale bar 200 μm) and (D) the myeloid hyperplasia is shown in the small red box (scale bar 200 μm).  
 
Specifically, in s-VANC, the fractures appeared repaired by a great amount of newly bone 
deposition in a remodeling phase (woven bone), coupled with a mild cortical thickening and 
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periosteal reaction. Both in l-VANC and s-rBMSCs, a complete closure of the fracture was found 
and the new bone appeared more mature and lamellar than in s-VANC. The l-VANC group showed 
uniformly enlarged cortices with areas of bone remodeling. 
Figure 9. Gram staining of the femurs at the day of explantation. The representative panel shows the 
Gram staining of the femurs in all the experimental groups. The panels depict an overview of the samples, 
scale bar 1 mm. In each group, the white boxes have a scale bar 10 μm and represent (A) detail of the s-
VANC group; (B) detail of the s-rBMSCs group; (C) detail of the l-VANC group; (D) detail of the l-rBMSCs 
group; (E, F) details of the PC group.  
 
In l-rBMSCs, 17% of samples presented only a partial bony bridging characterized by a great 
deposition of fibrovascular tissue invading the fracture site and surrounding the screws 
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disseminated with giant cells. In all the aforementioned groups, a moderate presence of 
polymorphonucleated cells was found within the medullary canal. The PC group showed 
disorganized bone architecture, a lot of fibrovascular tissues, and nonunion establishment. The 
periosteal reaction, myeloid hyperplasia, and presence of intact and fragmented 
polymorphonucleated cells in the granulation tissue associated with several vascular vessels 
represented signs of osteomyelitis. The Gram staining confirmed the quantitative data obtained 
from the microbiological tests (Figure 9). Indeed, in all groups, the presence of cocci was detected. 
In particular, s-VANC, s-rBMSCs, l-rBMSCs, and PC showed several cocci assembled in clusters 
and diffuse within the bone and periosteal tissue. Differently, l-VANC showed scarce dispersed 
cocci within areas of new bone formation in the fracture site.
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Discussion 
 
This comparative study analyzes for the first time the efficacy of systemic antimicrobial prophylaxis 
and antibacterial coating of orthopedic implants and cell therapy on MRSE-induced nonunions in 
rats. We hypothesized that the use of allogeneic MSCs could improve the host response to bacterial 
infections based on the potential immunomodulatory effects directly on the injured site [21]. In our 
study, the amount of systemically or locally injected rBMSCs was concordant with the dosage used 
in the literature for cardiovascular or autoimmune diseases [22, 23], as demonstrated to reach 
damaged sites. However, in our series, we had a 50% of animal death when intravenously injected 
with rBMSCs (s-rBMSCs). The histological analysis supported the “pulmonary first-pass theory,” 
in which a scarce cellular delivery has been demonstrated due to the lung filter in either animals or 
humans [24-27]. This phenomenon should be related to the cell adhesion, the activation of the 
coagulation pathway, and anaphylactic reactions promoted by the allogeneic MSCs causing 
pulmonary embolisms [23, 28]. Hereon, it is worth taking into account that the data obtained in the 
s-rBMSCs group considered only three animals and they cannot offer a good sample sizing to 
properly sustain our results, representing a limit of our study. The pathogenesis of bone infections 
after severe fractures is strictly related to the biofilm formation, making difficult both the diagnosis 
and the efficacy of treatments. Thus, identifying specific biomarkers would be crucial to early 
detection of the grade of infection. In our study, we evaluated cytokines produced in both the acute 
(IL-1a/b and TNF-a) and the chronic phases (IFN-g, IL-10, and IL-6) of inflammation/infection 
and involved in the bone remodeling (IL-6). Specifically, IL-6 has a bivalent function depending 
on the mode of expression: persistently high (even moderate) levels are associated with a pro-
inflammatory activity whilst a peaking behavior is associated with an anti-inflammatory pro 
regenerative effect [29]. However, the inability to discriminate between changes from postsurgical 
trauma and MRSE induced infection could represent a limitation. Overall, we demonstrated 
significant differences among groups after 7 days of infection. Due to the staphylococcal toxin 
release, TNF-a showed difference already at day 3, being the primary involved cytokine [30]. 
Moreover, we demonstrated the simultaneous activation of both pro- and anti-inflammatory 
cytokines. At day 7, higher IL-1a/b and TNF-a values in the PC group with respect to the others 
may have been in response to inflammatory stimuli because of bacterial growth and biofilm 
formation. This correlates with the greater neutrophil count at 14 days, when neutrophils mediate 
the recruitment of macrophages maintaining high levels of cytokines [31, 32]. Similarly, on day 7, 
s-VANC showed increased IL-1a/b and TNF-a values compared to the other treated groups, 
relating to a reduced efficacy of one-shot injected vancomycin. It is known that vancomycin acts 
both directly against bacteria and as an immunomodulatory drug, inhibiting the cytokine production 
during the early stages [33], as we also demonstrated at day 3. On day 14, higher cytokine levels in 
Discussion and Conclusions 
78 
l-VANC compared to the other groups could be caused by the local inflammatory response through 
the activation of macrophages that intervene against the material debris and could affect the bone 
repair, as also demonstrated by others [34]. Moreover, we detected high levels of IL-6 in l-VANC 
after 14 days, predicting a lower systemic efficacy of this treatment with respect to the conventional 
prophylaxis therapy [35]. However, IL-6 is involved in the modulation of bone cells during repair 
by suppressing the differentiation of the osteoclast progenitors [36, 37]. The increase of IL-1b, IFN-
a, and TNF-g found in l-rBMSCs at day 3 could be related to the antiapoptotic activity of MSCs on 
neutrophils in the microenvironment of a damaged and infected tissue [38, 39]. These data were 
also confirmed by the neutrophil analysis and were consistent with those described by Seebach et 
al. [13]. Furthermore, these inflammatory cytokines can stimulate the MSCs to release a large 
amount of growth factors promoting the tissue repair [40]. Again, we detected an up regulation of 
IL-10 in l-rBMSCs at days 7 and 14. Specifically, IL-10, produced by the macrophages present in 
the histological sections of l-rBMSCs, has a regulatory role in immunological and inflammatory 
responses by decreasing the production of pro-inflammatory cytokines, as demonstrated here and 
by others [41]. Indeed, the interaction between MSCs and macrophages secretes prostaglandin E2 
that reprograms the macrophages to release IL-10 [39]. The increase of IL-10 in l-rBMSCs suggests 
that MSCs can modulate the host immune response to infection. Otherwise, a similar behavior for 
the s-rBMSCs group could not be supported by this study because of the small number of survived 
animals. Thus, the clinical results in the s-rBMSCs group (micro-CT and histology) cannot be 
considered representative for the efficacy of this treatment. Concerning the other groups, the semi-
quantitative Odekerken’s score for osteomyelitis was supported by the BV and TMD 
measurements, in which no significant differences were found among s-VANC, l-VANC, and l-
BMSCs groups. The micro-CT and histological analyses of the PC group generated results 
consistent with those of our previous study [15], demonstrating the development of septic 
nonunions. The same analyses highlighted a worse osteomyelitis score in the l-rBMSCs group 
compared to the antibiotic treated groups, as also supported by Seebach et al. [13]. This is 
potentially due to the release of cellular proteases by dead MSCs that could negatively act on bone 
repair and support the bacterial colonization. This was also demonstrated by the microbiological 
tests measuring a greater bacterial growth in l-rBMSCs compared to the antibiotic treated groups. 
Overall, our study demonstrated a good response in terms of bone healing and absence of 
osteomyelitis in s-VANC and l-VANC.  
 
 
 
 
Discussion and Conclusions 
79 
Conclusions  
Through our results, we could suggest the synergic use of systemically injected vancomycin and its 
local delivery as an effective treatment to prevent the bacterial spread in orthopedic infections. The 
hydrogel, used in this study, could also ameliorate the bone repair towards a more mature bone 
thanks to its capability in stimulating bone specific cytokine (IL-6). Otherwise, our study cannot 
definitely sustain the use of cell therapy for this purpose. Indeed, the intravenous injection of MSCs 
should be considered a highly risky treatment with a high rate of mortality. However, based on our 
preliminary results on the local injection of MSCs, a deeper insight into their immunomodulatory 
mechanisms in a large experimental design should be helpful to develop novel strategies for the 
clinical use of MSCs. 
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Abstract  
We announce the draft genome sequence of Staphylococcus epidermidis clinical strain 
GOI1153754-03-14 isolated for an infected orthopedic prosthesis. The reported genomic sequence 
will provide valuable information concerning the mechanisms of the biofilm formation on metallic 
implants.  
 
Implant-related infections are the most severe complications following joint arthroplasty and 
represent a socioeconomic burden. Consequently, it is important to pore over the interaction 
between pathogens and the host immune response along with the mechanisms leading to prosthetic 
infections [1]. This complex process starts with bacterial contamination, adhesion and biofilm 
formation on the implant surface, thus conferring to bacteria a protection from both the host immune 
system and antibiotics [2].  
Among several pathogens involved in implant-related infections, staphylococci account for 82.3% 
of clinically isolated bacteria. In the presence of medical devices, S. aureus infection accounts for 
31.7 % of all isolates, while S. epidermidis accounts for 39 % [3].  
Staphylococcus epidermidis is a commensal gram positive, coagulase negative pathogen 
responsible for delayed, low-grade nosocomial infections characterized by the absence of specific 
clinical signs and hardly distinguishable from aseptic prosthetic loosening [4, 5].  
In this work, we announce the draft genome sequence of S. epidermidis clinical strain GOI1153754-
03-14 derived from an infected knee prosthesis of a patient undergone implant revision at the Center 
for Reconstructive Surgery of Osteoarticular Infections (C.R.I.O., IRCCS Galeazzi Orthopedic 
Institute, Milan, Italy), and isolated at the Laboratory of Clinical Chemistry and Microbiology 
(IRCCS Galeazzi Orthopedic Institute, Milan, Italy).  
The antimicrobial susceptibility and minimum inhibitory concentration (MIC) of this strain were 
carried out on Vitek2 System (Biomerieux, Craponne, France), displaying resistance to 
benzylpenicillin (MIC ≥ 0.5 µg/ml), oxacillin, cefazolin, rifampicin and levofloxacin (MIC ≥ 4 
µg/ml) [6]. 
Genomic DNA from bacterial culture was extracted using the Bacterial Genomic DNA Isolation 
Kit (Norgen Biotek Corp., Thorold, ON, Canada) according to the manufacturer’s guidelines, and 
quantified through the NanoDrop 2000 UV-Vis Spectrophotometer (Thermo Fisher Scientific Inc., 
Waltham, MA, USA). 
Libraries were prepared by means of the ThruPLEX DNA-seq (Rubicon Genomics, Ann Arbor, 
MI, USA). The isolate was sequenced on the Illumina MiSeq platform through the MiSeq Reagent 
Kit v3 (600-cycles) to produce 300 bp paired-end reads (Illumina Inc., San Diego, CA, USA).  
The outputs were quality-trimmed using ERNE-Filter [7] into 51 contigs (Average = 50,720.6 Mb; 
Max = 280,473 Mb; Min = 633 Mb) with 396X fold average coverage. The combined length of the 
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contigs was 2,586,753 bp with a GC content of 31.84% and an N50 value of 7 bp. Gene annotations 
were performed thorough the RAST software [8], resulting in a total of 2,467 protein-encoding 
genes and 64 RNAs (55 tRNAs and 9 rRNAs). 
Since the ability of S. epidermidis GOI1153754-03-14 to colonize implants and to cause septic non-
unions was already validated in a recent in vivo study [6], the deposition of the draft genome 
sequence will enable to have a deeper insight into the mechanisms of prosthetic joint infections. 
Accession number(s). The genome shotgun has been deposited in DDBJ/ENA/GenBank under the 
accession no. FWCG01000000. The version described in this paper is the first version, 
FWCG01000000. 
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Introduction 
 
Prosthetic joint replacements are widely performed orthopedic procedures, being effective 
therapeutic options in the case of severe osteoarthritis. Indeed, arthroplasties are characterized by 
high rates of success by giving long-term pain relief and by restoring joint function [1]. As 
population age increases, the incidence of total hip and knee arthroplasties also increase along with 
this global trend. In the USA alone, the number of joint replacements is currently over one million 
and are expected to reach four million by 2030 [1].  
Despite excellent clinical results, prosthetic joint replacements have complications including 
persistent pain, implant loosening and infections that lead to revision surgery.  
In particular, prosthetic joint infections (PJI) are one of the major causes of failure that requires the 
replacement of the implant and has a burdensome impact on patient quality of life and 
hospitalization costs [2]. PJI are usually caused by an accidental bacterial contamination which 
occurs in the operating room. The pathogens involved in are those able to colonize orthopedic 
devices and to form biofilm on the implant surface, include Staphylococcus aureus, Staphylococcus 
epidermidis and Pseudomonas aeruginosa [3]. In particular, staphylococci account for 82.3% of 
clinically isolated bacteria and, in the presence of medical devices, S. aureus isolates account for 
31.7 %, while S. epidermidis accountfor 39 % of all isolates [4]. 
Recently, S. epidermidis has been identified as an emergent low virulence pathogen implicated in 
numerous nosocomial infections associated with medical devices (e.g. catheters, pacemakers, metal 
implants etc.) [5]. S. epidermidis is a commensal Gram positive, coagulase negative bacteria and, 
depending on the biological context in which it grows, it could be either a symbiont or a pathogen 
implicated in delayed infection characterized by the absence of specific clinical signs barely 
distinguishable from aseptic prosthetic failure [6]  
In contrast to S. aureus, S. epidermidis does not encode many pathogenicity islands and its major 
virulent property is the ability to establish organized communities which regulate the expression of 
genes involved in survival mechanisms and biofilm formation on implants [7, 8]. Indeed, biofilm 
confers a protective niche to S. epidermidis in which sessile bacteria can grow and evade host 
immune defenses and antimicrobial treatments, leading to the development of antimicrobial-
resistant strains, such as methicillin-resistant S. epidermidis (MRSE) [8]. The complete pathway 
that regulates biofilm formation in vivo has been studied and divided in to four progressive steps 
involving the expression of specific proteins: attachment, accumulation, maturation and detachment 
[9]. The attachment phase is characterized by the expression of proteins related to bacterial 
adherence to the surface of the device (e.g. adhesins/autolysins AltE and Aea, Microbial Surface 
Components Recognizing Adhesive Matrix Molecules MSCRAMMs etc.). The accumulation and 
maturation steps are characterized by the synthesis of proteins responsible for intercellular adhesion 
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(Polysaccharide Intercellular Adhesin, PIA), formation of fibril-like structures (Accumulation 
Associated Protein, Aap) and also formation of channels to ensure the supply of nutrients and 
oxygen to bacteria throughout the thick biofilm (Phenol-soluble Modulins, PSMs) [7, 10]. The last 
phase is detachment, in which bacteria separate from the mature matrix and disperse throughout the 
host: this phase has a crucial evolutionary importance for the spread of the infection. An in vivo 
study demonstrated how the detachment phase depends on a well-characterized quorum-sensing 
system (accessory gene regulator, agr), through an agr mutant bacterial strain in a rabbit model of 
medical device–related infection [11].  
The purpose of the present study was to analyze proteins expressed in a mature biofilm on metallic 
implants. Thus, the proteomic profiles of two different strains of MRSE were compared when 
growing in planktonic and sessile forms. The analysis of the proteins expressed under these 
different culture conditions after 72 hours of culture might describe both the mechanisms behind 
biofilm steady state and the differences between the two tested bacterial strains. Potentially, this 
study, based on the characterization of the regulation of prokaryotic cells, could lead to new 
diagnostic biomarkers or therapeutic targets to detect latent and chronic infections mediated by low 
virulence pathogens such as S. epidermidis. 
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Materials and Methods 
 
MRSE isolation and phenotypic characterization 
Methicillin-resistant Staphylococcus epidermidis GOI1153754-03-14 analyzed in this study was 
isolated from an infected knee prosthesis of a patient who underwent revision surgery at the Center 
for Reconstructive Surgery of Osteoarticular Infections (C.R.I.O., IRCCS Galeazzi Orthopedic 
Institute, Milan, Italy). The isolate was subsequently characterized at the Laboratory of Clinical 
Chemistry and Microbiology of the IRCCS Galeazzi Orthopedic Institute (Milan, Italy).  
The phenotypic characterization of the microorganism was performed by means of VITEK2 System 
(Biomerieux) using the card AST 632 specific for staphylococci. This evaluation defined the 
antimicrobial susceptibility of the strain along with the minimum inhibitory concentration (MIC) 
of a panel of antibiotics.  
Furthermore, the capability of the MRSE GOI1153754-03-14 to produce biofilm was tested in vitro 
according to a spectrophotometric assay [12]. Briefly, a 0.5 McFarland suspension was prepared 
and 20 µl were inoculated in 96-well plates containing 180 µl of Tryptose Soy Broth (TSB; 
BioMérieux). Wells containing 200 µl of TSB were used as negative controls. After a 48-hour 
incubation at 37°C, wells were washed with phosphate buffered saline (PBS; Gibco) to remove 
floating bacteria not embedded in the biofilm. The biofilm was dried under a laminar flow hood 
and, subsequently, 200 µl of 5% crystal violet solution (Merck) were added into each well and 
incubated at room temperature (RT) for 10 minutes, then the wells were washed three times with 
PBS to remove any dye excess. After air-drying, the dye attached to the biofilm was solubilized 
using 200 µl of absolute ethanol and the optical density (OD) of each well was measured at 595 nm 
by using a microplate reader (Multiskan FC, Thermo Scientific). The strain was classified as a 
strong, moderate or weak biofilm producer [13]. 
 
MRSE genotypic characterization 
The entire genome of MRSE GOI1153754-03-14 was sequenced and the sequence has been 
deposited at the European Nucleotide Archive (ENA) under the accession number FWCG01000000 
[14]. Briefly, genomic DNA from bacterial culture was extracted using the Bacterial Genomic DNA 
Isolation Kit (Norgen Biotek Corp.) according to the manufacturer’s guidelines, and quantified 
using the NanoDrop 2000 UV-Vis Spectrophotometer (Thermo Fisher Scientific Inc.). Libraries 
were prepared by means of ThruPLEX DNA-seq (Rubicon Genomics), then sequenced on the 
Illumina MiSeq platform through the MiSeq Reagent Kit v3 (600-cycles) to produce 300 bp paired-
end reads (Illumina Inc.). Outputs were quality-trimmed using ERNE-Filter [15] and the sequence 
assembled with CLC assembly cell software (Qiagen). Finally, gene annotation was performed 
using RAST software [16].
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Comparative genome analyses 
Comparative genome analysis was first carried out by means of BLAST (Basic Local Alignment 
Search Tool, http://blast.ncbi.nlm.nih.gov). The genome of the GOI1153754-03-14 clinical isolate 
was inserted as a query sequence and compared to S. epidermidis genome sequences deposited in 
GeneBank, in order to explore the mechanisms underlying GOI1153754-03-14 pathogenicity.  
Moreover, the genomes of S. epidermidis GOI1153754-03-14 and ATCC 35984 were compared 
against each other to identify the conserved domains shared by the two strains using a Java-based 
tool called Mauve (http://asap.ahabs.wisc.edu/mauve/), able to align different genomic sequences 
[17]. Briefly, the sequences without contigs were loaded as input and analyzed. The output was 
plotted in a series of colored blocks each representing a gene, making it easier to visualize the 
conserved regions among the genome.  
 
Planktonic and sessile culture of MRSE GOI1153754-03-14 and ATCC 35984  
GOI1153754-03-14 and ATCC 35984 MRSE were cultured both in their planktonic and sessile 
forms. Planktonic cultures were grown in triplicate under vigorous agitation (200 rpm) in Brain 
Heart Infusion broth (BHI, Biomerieux) at 37°C under aerobic conditions. After 72 hours, the 
bacterial suspensions were centrifuged at 3000 rpm for 10 minutes at 4°C in order to collect 
triplicate 50 mg bacterial pellets. The cell pellets were carefully washed six times with ice-cold 
PBS and, after the removal of the supernatant, the pellets were stored at -20 °C until use.  
To obtain sessile culture samples, bacteria were grown on sandblasted titanium disks to mimic 
bacterial biofilm formation on prosthetic implants, as previously reported [2]. Briefly, sterile 
sandblasted titanium disks (Ø 25 mm; thickness 5 mm) (Adler Ortho, Italy; batch J04051) were 
incubated in six-well plates containing 5 ml of fresh BHI and approximately 1.5 x 108 CFU/ml of 
MRSE GOI1153754-03-14 or ATCC35984. Plates were then incubated at 37°C under aerobic 
conditions for 72 hours. At the end of the experiment, the titanium disks were washed three times 
with ice-cold PBS and scraped with a sterile silicone cell scraper (VWR International) on ice. The 
bacterial suspensions were centrifuged and washed as previously described in order to collect 
triplicate 50 mg bacterial pellets. All the samples were then stored at -20°C for later analysis.  
 
Protein extraction and quantification  
The bacterial pellets obtained from the planktonic and sessile cultures of MRSE GOI1153754-03-
14 and ATCC 35984 were suspended at a 1:10 (w/v) ratio in rehydration buffer containing 7M urea, 
2M thiourea, 2% 3-[(3-Cholamidopropyl) dimethylammonio]-1-propanesulfonate hydrate 
(CHAPS) supplemented with a mix of protease inhibitors and nucleases (GE healthcare), according 
to the manufacturer’s instructions. The samples were processed using six cycles of 60 sec bead 
beating at 4000 rpm (MiniLys, Bertin Technologies) using 0.1 mm Zirconium Silica beads 
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(BioSpec USA), added in the ratio of 1:1 (w/v) to the pellet suspension. Bead beating was 
interspersed by 5 min cooling on ice and 5 min centrifugation at 2°C and 20000 g. After the bead 
beating cycles, the samples were centrifuged at 20000 g at 2°C for 30 min. Supernatants were 
collected and the protein concentration in the samples was determined using the Bradford assay 
(BioRad Protein Assay). Absorbance was measured using a spectrophotometer (Gene Quant 100, 
GE Healthcare) at 595 nm. The extracted proteins were stored at -80°C for later analysis.  
 
2-DE 
Proteins were separated using two-dimensional electrophoresis (2-DE). For the isoelectric focusing 
(IEF) step, immobilized pH gradient (IPG) polyacrilamide gel strips (GE Healthcare, 7 cm, pH 4.0-
7.0) and Protean IEF Cell (Bio Rad) were utilized. Prior to IEF, 100 µg of protein sample was 
dissolved in a solution containing 7 M urea, 2 M thiourea, 2% w/v CHAPS, 30 mM DTT, 0.5% w/v 
ampholine (pH 3.5-10.0) and 1% w/v bromophenol blue. IPG strips were first actively rehydrated 
in the presence of the sample at 50 V and 20°C for 16 h. After the rehydration step, paper wicks 
soaked in milliQ water (8 µl) were placed between the cathode, the anode and the gel strip to prevent 
the burning of the strips caused by high voltage. The voltage was gradually increased according to 
the following protocol: 100 V (4 h), 250 V (2 h), 5000 V (5 h), 5000 V until the cumulative voltage 
reached 50 kVhand a maximum current of 50 µA per gel strip. Following IEF, each strip was 
chemically reduced for 15 min in 5 ml of solution containing 6 M urea, 2% w/v SDS, 50 mM Tris-
HCl buffer, pH 8.8 and 30% v/v Glycerol with 1% w/v DTT added, and then alkylated in 5 ml of 
the same solution with 2.5% w/v of IAA added in place of DTT. IPG strips were then briefly washed 
in 1x running buffer (25 mM Tris-HCl, pH 8.8, 192 mM glycine, 0.1% w/v SDS), loaded onto 10% 
w/v polyacrylamide gels along with the protein ladder and fixed in place with 0.5% w/v low melting 
point agarose. The second dimension was carried out in a Mini-Protean Tetra system (Bio Rad). In 
the first step of electrophoresis, 8 mA per gel were applied for 15 min until the bromophenol blue 
front line entered the gel . In the second step, 16 mA per gel were applied until the bromophenol 
blue front line reached the bottom of the gel. Gels were left overnight to stain in 100 ml of 
Coomassie Blue G-250 solution (Sigma-Aldrich).  
 
Image acquisition and analysis 
2-DE maps were acquired using a flatbed densitometer (ImageScanner III, GE Healthcare, 
Uppsala). Variations in protein expression were analyzed using the Progenesis SameSpots 4.6 
(Nonlinear Dynamics, UK). The module for 2-DE gel analysis was used which aligns images, 
removes and detects background, normalizes and matches spots.  
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Protein identification 
Protein identification was carried out as described [18]. Briefly, analysis was performed on an 
Ultraflex III MALDI-TOF/TOF spectrometer (Bruker-Daltonics) in positive reflectron mode. For 
the external calibration, the standard peptide mixture calibration (Bruker-Daltonics: m/z: 
1046.5418, 1296.6848, 1347.7354, 1619.8223, 2093.0862, 2465.1983, 3147.4710) was used. To 
select monoisotopic peptide masses, mass spectra were analyzed with FlexAnalysis 3.3 software 
(Bruker-Daltonics). After an internal calibration (known autolysis peaks of trypsin, m/z: 842.509 
and 2211.104) and exclusion of contaminant ions (known matrix and human keratin peaks), the 
created peak lists were analyzed by MASCOT v.2.4.1 algorithm (www.matrixscience.com) against 
SwissProt 2017_06 database restricted to Staphylococcus epidermidis taxonomy (20238 
sequences). For the database search, the following parameters were established: 
carbamidomethylation of cysteines and oxidation on methionines (set respectively among fixed and 
variable modifications) one missed cleavage site for trypsin and maximal tolerance established at 
70 ppm. For protein identification assignment only Mascot scores higher than 56 were considered 
significant (p < 0.05). To confirm the identification obtained, MS/MS spectra were acquired by 
switching the instrument in LIFT mode with 4–8 × 103 laser shots using the instrument calibration 
file. For fragmentation, precursor ions were manually selected and the precursor mass window was 
automatically set. For each MS/MS spectra acquired, spectra baseline subtraction, smoothing 
(Savitsky–Golay) and centroiding were operated using Flex-Analysis 3.3 software. The following 
parameters were used for the database search: among fixed and variable modifications, 
carbamidomethylation of cysteines and oxidation on methionine, maximum of one missed cleavage 
and the mass toleranceset to 50 ppm for precursor ions and to a maximum of 0.4 Da for fragments. 
The taxonomy was restricted to Staphylococcus epidermidis (20238 sequences). The confidence 
interval for protein identification was set to 95% (p < 0.05) and only peptides with an individual 
ion score above the identity threshold were considered correctly identified. 
 
Statistical analysis 
Statistical analysis was performed using the Progenesis Stats module on log-normalized volumes 
for all spots. The progenesis stats module automatically performs a One-way ANOVA on each spot 
to evaluate the p value between different groups, p-values under 0.05 were considered statistically 
significant. 
Multiple comparisons among groups were analyzed using two-way ANOVA (Prism 5, GraphPad) 
and then corrected with Tukey’s post hoc test. All data are expressed as means ± standard deviation 
(SD). Values of 𝑝 < 0.05 were considered statistically significant. 
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Results 
 
Phenotypic and genotypic characterization of MRSE GOI1153754-03-14 
Antimicrobial susceptibilities along with the MIC values of S. epidermidis GOI1153754-03-14 are 
reported in Table 1.  
 
Table 1. Antimicrobial susceptibilities and MIC values of MRSE GOI1153754-03-14 
 
Antibiotic Antimicrobial susceptibility MIC (µg/ml) 
Benzylpenicillin Resistant ≥ 0.5 
Oxacillin Resistant ≥ 4.0 
Levofloxacin Resistant 4 
Rifampicin Resistant ≥ 4.0 
Gentamicin Susceptible ≤ 0.5 
Erythromycin Susceptible ≤ 0.25 
Clindamycin Susceptible ≤ 0.12 
Linezolid Susceptible 1 
Daptomycin Susceptible 0.25 
Teicoplanin Susceptible 4 
Vancomycin Susceptible ≤ 0.5 
Tetracycline Susceptible ≤ 1 
Tigecycline Susceptible ≤ 0.12 
Fusidic acid Susceptible ≤ 0.5 
Trimethoprim Susceptible ≤ 10 
Sulfamethoxazole Susceptible ≤ 10 
 
The study of antimicrobial susceptibilities enable the comparison of the clinical isolate with that of 
ATCC 35884, showing comparable MIC values especially for vancomycin susceptibility [19].  
The spectrophotometric assay demonstrated the ability of the clinical isolate to form biofilm in 
vitro. Based on the obtained OD values (OD/ODc = 6.38, where ODc is the OD cut-off as three SD 
above the mean OD of the negative control [13]), the clinical isolate was classified as a strong 
biofilm producer. 
Whole genome sequencing resulted in the identification 51 contigs in GOI1153754-03-14 (Average 
= 50,720.6 Mb) with 396X fold average coverage. In Table 2 the genome characteristics of the 
clinical isolate GOI1153754-03-14, compared to those of ATCC 35984 already reported in the 
Results 
97 
literature, are summarized [20]. 
 
Table 2. Comparison of genome characteristics of S. epidermidis GOI1153754-03-14 and ATCC 35984 
 GOI1153754-03-14 ATCC 35984 
Genome Size (bp) 2,586,753 2,616,530 
C+G Content (%) 31.84 32.15 
N° Genes 2,467 2,562 
N° rRNA 9 19 
N° tRNA 55 61 
Accession Number FWCG01000000 CP000029 
Reference [14] [20] 
 
Comparative genome analyses 
The genome sequences of S. epidermidis GOI1153754-03-14 (query sequence) and ATCC 35984 
(reference strain) were first compared against each other by means of BLAST software. The 
obtained alignment score is reported in Table 3.  
 
Table 3. Alignment scores elaborated by BLAST algorithm. 
Max score Total score Query 
cover 
E 
value 
Identities Ident Gaps 
3.123 x 105 4.969 x 106 90% 0.0 169324/169429 99% 11/169429 (0%) 
 
The alignment scores revealed a high homology of the genomic sequences of the two S. epidermidis 
strains, with a significant E value (E value < 0.05).  
To visualize the homologous regions shared by S. epidermidis GOI1153754-03-14 and ATCC 
35984, the genomes were analyzed by means of Mauve software and the output is reported in Figure 
1. 
The upper part of the output is the ATCC 35984 genomic sequence, while the lower part is 
GOI1153754-03-14. Blocks belonging to the clinical isolate below the center line indicate regions 
that align in the reverse complement (inverse) orientation. White parts represent not aligned regions 
or genomic areas that are not shared by the two strains.  
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Figure 1. Mauve alignment of S. epidermidis GOI1153754-03-14 and ATCC 35984 genome.  
 
Protein identification through 2-DE coupled with MALDI TOF/TOF MS 
The proteins differently expressed among S. epidermidis GOI1153754-03-14 and ATCC 35984 in 
their planktonic and sessile forms were subsequently identified.  
All the 2D maps resolved approximately 573±10 protein spots. From gel imaging analysis, a total 
of 7 proteins were found to be differentially expressed in planktonic and sessile bacteria in the two 
S. epidermidis strains (p<0.05) (Figure 2). In particular, 3 of the analyzed proteins were up-
regulated and 4 down-regulated in biofilm forming S. epidermidis.  
 
 
Figure 2. Two representative 2D gels showing differentially expressed proteins after Coomassie Blue 
staining. Numbers refer to proteins identities on the gels.  
 
The list of the identified proteins is reported in Table 4, along with their expected molecular weights 
and isoelectric points, and the obtained Mascot scores; the quantification of the differentially 
expressed proteins according to the strain and culture conditions are presented in Figure 3. 
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Table 4. List of the identified proteins along with their UniProt accession numbers, expected molecular 
weights (kDa) and isoelectric points (pH) and Mascot scores.  
 
Spot 
N° 
UniProt 
code 
Protein name Exp-
Mass 
(Da) 
Exp. 
pI 
Mascot 
PMF 
score 
Mascot 
MS/MS 
score 
815 Q5HNJ5 Putative universal 
stress protein 
18469 5.44 103 120 
1282 Q5HQR8 Organic hydroperoxide 
resistance protein-like 
1 
15459 4.70 66 70 
1283 Q5HM88 S-ribosylhomocysteine 
lyase 
17806 5.09 59 86 
571286 Q5HP76 Nucleoside 
diphosphate kinase 
16749 5.68 88 86 
1287 Q5HRD6 Alcohol dehydrogenase 36834 5.00 92 86 
 
Among the differentially expressed proteins, the putative universal stress protein (Y1273_STAEQ 
- Q5HNJ5), a cytoplasmic protein expressed by the gene SERP1273 of S. epidermidis ATCC 
35984, was identified. Y1273_STAEQ is physiologically expressed in response to stress conditions 
such as starvation, temperature shock, or in response to the presence of inhibitory agents [21]. This 
protein was significantly downregulated in both S. epidermidis GOI1153754-03-14 and ATCC 
35984 in sessile forms (p<0.05 and p<0.001, respectively). Interestingly, the planktonic culture of 
ATCC 35984 had a a significant increase in the expression of this protein compared to the clinical 
isolate grown under the same culture conditions (p<0.01).  
Similarly, organic hydroperoxide resistance protein-like 1 (OHRL1_STAEQ - Q5HQR8), another 
cytoplasmic protein expressed by the gene SERP0480 in response to oxidative stress, was 
downregulated in both S. epidermidis strains when grown in sessile forms.  
Another downregulated protein expressed by both sessile bacteria was S-ribosylhomocysteine lyase 
(LUXS_STAEQ - Q5HM88). This protein is secreted by bacteria in response to an increase in cell 
density, by a mechanism called quorum sensing (QS). Through QS, bacteria can modulate their 
phenotype regulating gene expression in response to stress. LuxS was particularly downregulated 
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in biofilm forming S. epidermidis ATCC 35984 when compared to its planktonic counterpart 
(p<0,001).  
Of the three proteins which showed increased expression as a result of biofilm development, 
nucleoside diphosphate kinase (NDK_STAEQ - Q5HP76) was identified. This housekeeping 
enzyme was particularly upregulated in the sessile clinical isolate both when compared to its 
planktonic counterpart and when compared to sessile ATCC 35984 (p<0.001 and p<0.01, 
respectively). Ndk is a highly conservative bacterial protein with a crucial role in the biosynthesis 
of nucleoside triphosphates and in the synthesis of polysaccharides [22, 23].  
Finally, among the differentially expressed proteins, we identified the alcohol dehydrogenase 
(ADH_STAEQ - Q5HRD6), a protein involved in different biological pathways such as glycolysis, 
gluconeogenesis, fatty acid and naphthalene degradation, biosynthesis of secondary metabolites in 
diverse environments and degradation of aromatic compounds [24]. Once again, this protein was 
downregulated in both S. epidermidis GOI1153754-03-14 and ATCC 35984 in the sessile forms 
(p<0.001 and p<0.05, respectively).  
Unfortunately, we were not able to identify the other two proteins upregulated both in sessile S. 
epidermidis GOI1153754-03-14 and ATCC 35984 (data not shown).  
 
 
 
Figure 3. Quantification of the identified proteins. The histograms represent the normalized volumes 
of the spots determined by Progenesis SameSpots software. Data are expressed as mean ± SD. Statistical 
significance for p<0.05 (*), p<0.01 (**) and p<0.001 (***). 
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Discussion 
 
Although staphylococcal biofilms have been extensively studied, it is a common erroneous belief 
that cells within the biofilm matrix are exposed to the same external conditions [25]. Biofilm is a 
dynamic system in constant development that permits the survival of bacteria in hostile 
environments [26]. The structure of mature biofilms is complex and well-organized; there are 
channels providing nutrients to cells that circulate through the biofilm matrix [27], and bacteria in 
different regions of the same matrix might exhibit different gene expression patterns according to 
their exposure to external agents [28]. 
As staphylococcal biofilms mature, it is well-known that the QS regulated expression of the agr 
dependent system leads to the release of individual cells [9]. However, biofilm can protect bacteria 
for long periods of time quietly without being detected by the host immune system. In this particular 
scenario, it is challenging to define therapeutic targets or diagnostic biomarkers to detect latent or 
chronic infection mediated by low virulence, biofilm forming bacteria, as S. epidermidis.  
In the present work, mature biofilms of two different S. epidermidis strains were studied using a 
proteomic approach to evaluate the induction or repression of individual proteins, as a result of 
sessile or planktonic culture. The obtained data revealed that many changes in protein expression 
in both S. epidermidis strains occurred when planktonically cultured. In particular, the analysis of 
the proteins expressed by planktonic bacteria revealed results linked to bacterial stress, also reported 
elsewhere in the literature [29]. Indeed, the upregulation of the putative universal stress protein 
(Q5HNJ5) is a common response to stress, probably due to elevated cell density in the culture media 
after 72 hours incubation [29]. The universal stress protein A (uspA) superfamily is a conserved 
group of proteins expressed in many different species such as bacteria, fungi, Archaea and insects 
[21]. A high cell density in a close environment without renewed nutrient supplies inevitably 
provokes an alteration of physiological cell balance; harsh conditions such as nutrient deprivation, 
pH decrease, exposure to oxygen and nitrogen species predictably lead to global stress responses 
[30]. 
Based on these assumptions, the higher expression of Ohrl-1 (Q5HQR8) and LuxS (Q5HM88) in 
S. epidermidis when planktonically cultured can be explained in light of stress. Ohrl-1 (Q5HQR8) 
is a highly conserved protein identified in many different bacterial species, such as Bacillus subtilis 
[31], Pseudomonas aeruginosa [32], Actinobacillus pneumoniae [33], etc. This protein belongs to 
the peroxiredoxin family, considered to be the primary cellular protector against oxidative stress in 
all living organisms, detoxifying organic peroxides while favoring microbial survival [34]. Indeed, 
staphylococci evolved many oxidative defense strategies that allow them to face the near constant 
challenge of surviving in the presence of exogenous and endogenous oxidants [35]. 
As cell density increases, the QS system is activated in order to coordinate the expression of 
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different genes in response to cell density through small signaling molecules, called autoinducers 
(AIs) [36].  
LuxS (Q5HM88) is involved in the synthesis of the autoinducer-2, a QS signaling pheromone 
expressed both by Gram positive and negative bacteria [37]. The mechanisms of LuxS activation 
and regulation are still unclear [38], however, its upregulation is known to be closely connected to 
QS stress [39, 40]. The lack of LuxS enzyme in humans made this protein an attractive target for 
new therapeutic agents [41], however inhibitors of LuxS enzymes actively increase the virulence 
of S. epidermidis, increasing their ability to form biofilm [36]. Indeed, in S. epidermidis, the LuxS 
system negatively affects the expression of polysaccharide intracellular adhesin (PIA) and, 
consequently, the synthesis of extracellular matrix [42]. 
Among the downregulated proteins expressed by sessile S. epidermidis, we also identified Adh 
(Q5HRD6). In the literature, there a little information concerning the role of Adh in planktonic 
cells, however there is some evidence of increased Adh expression in Candida albicans cells grown 
in suspension compared to biofilm forming cells [43]. Moreover, Mukherjee and colleagues 
reported that the inhibition of this enzyme leads to greater biofilm production in vitro.  
In contrast to the upregulation of stress-related proteins found in planktonic bacteria, biofilm 
forming S. epidermidis demonstrated a superior resistance to various stress conditions during 72 
hours of culture. This phenomenon can be easily explained by the protection that the self-produced 
EPS matrix confers to sessile bacteria [44]. After 72 hours of static culture on titanium disks, both 
S. epidermidis GOI1153754-03-14 and ATCC 35984 were metabolically active, which we can 
assume by the upregulation of the nucleoside diphosphate kinase (Ndk, Q5HP76). The main role 
of Ndk is the biosynthesis of nucleoside triphosphates other than ATP (CTP, UTP and GTP) 
(UniRule: UR000089065). Due to its housekeeping function, Ndk is a highly conserved enzyme 
that can be found in both eukaryote and prokaryote cells [45]. Furthermore, in addition to its 
phosphotransferase activity, Ndk plays an active role in bacterial virulence. As reported by Yu and 
colleagues [23], depending on its intracellular or extracellular expression, it can suppress a series 
of host defense mechanisms (e.g. phagocytosis, inflammatory response, cell death, etc.) or can have 
a cytotoxic effect on host cells.  
Unfortunately, the two proteins that were not identified in this study were both upregulated in 
sessile S. epidermidis GOI1153754-03-14 and ATCC 35984. The inability to identify the proteins 
was probably due to the very low amount expressed during the experimental conditions which fell 
below the limit of detection of the instrument. Along with the need to identify these spots, there is 
also the need to verify if upregulation of the stress-related proteins in planktonic S. epidermidis is 
related to the choice of a late sample time point.  
For this reason, a future study involving proteomic analysis of S. epidermidis GOI1153754-03-14 
and ATCC 35984 performed at different time points may overcome limitation due to the cell 
density. 
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Non-union fractures, as a severe failure of bone healing, are among the most difficult and 
challenging orthopedic complications. Non-unions represent a clinical burden, as well as a socio-
economic encumbrance that decreases the quality of patients’ lives and requires surgical treatment 
and long recovery times which increases the burden on the National Health Service. Depending on 
the type of surgery and depending on the health status and age of the patients, orthopedic 
complications can be severe; it has been estimated that fracture healing, for example, is delayed in 
600,000 patients per year in the United States alone, and approximately 100,000 of the fractures 
result in non-unions [1]. The percentage of fractures leading to non-union is between 5 and 10% 
and generally occurs in long bones like tibia, femur, humerus, radius, and ulna. The triggering 
events leading to non-union development might be linked to old age, poor compliance with 
rehabilitation, smoking, alcoholism, diabetes, and immunodeficiency. Moreover, orthopedic 
complications might result in non-union development due to inadequate fracture treatments, like 
poor mechanical stability or, again, due to the administration of pharmacological agents such as 
steroids, ciprofloxacin, chemotherapy drugs, etc., or due to excessive movement of the patients [2]. 
Non-union might also be the result of severe trauma characterized by open fracture with significant 
bone loss, soft tissue damage and contamination, which can increase by a factor of 19 the rate of 
septic non-union development [3].  
Furthermore, in the presence of orthopedic devices used in the case of osteosynthesis (e.g. 
prosthesis, wire, plate screw, etc.), the incidence of infection increases because the surface of these 
implants offers the perfect substrate for bacterial adhesion and growth [4]. Loss of life or limb due 
to infection is very rare, but still occasionally occurs. Therefore, to keep the risk as low as possible, 
patients undergoing orthopedic surgery are treated with antibiotics as prophylaxis. Despite 
prophylaxis, there is a 1-4% chance of developing a deep infection extending to the bone, 
surrounding soft tissues, and to the implanted medical device [5, 6]. In these cases, revision surgery 
is required to remove both the infected tissues and implants in order to eradicate the infection [7, 
8].  
Hence, there is the real need to minimize the risk of implant-related infections, emphasizing 
prophylaxis measures while discouraging the impairment of bone healing. Consequently, the 
design, development and use of preclinical models are necessary steps to investigate the 
pathogenesis of septic non-unions as major consequence of infection of the fracture site. 
With this aim, in the first phase of the project, we developed three preclinical models of infected 
non-unions able to resemble the clinical features of nosocomial implant-associated infection caused 
by a low virulence pathogen (Chapter 1). The development of these models provides a standardized 
tool to study preventive and therapeutic strategies in the case of subclinical, sub-acute and chronic 
onset of septic non-unions. 
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Indeed, despite the large number of animal models of infected fractures described in the literature, 
there are several limitations in comparing them due to the use of different bacterial strains, 
concentrations and fracture stabilization methods [9]. Indeed, these studies are mainly focused on 
the analysis of bone repair through the assessment of critical size defects in long bones, in the 
presence of virulent bacteria (e.g., S. aureus, Escherichia coli, Pseudomonas aeruginosa, etc.) [10-
14]. No models of S. epidermidis-mediated septic non-unions have been described so far. This 
variety of conditions encouraged us to focus our efforts on the development of more reproducible 
preclinical models to assess the role of S. epidermidis in the impairment of bone healing to provide 
relevant information to be translated to clinics [15].  
There are many characteristics that distinguish a reliable animal model of septic non-union; first of 
all, the stabilization of the fracture. Indeed, the lack of stability of the fracture will result in the 
failure of bone healing even in the absence of bacteria. Therefore, in our models of septic non-
unions, we used plates and screws as the fixation method to standardize the stability of fractures in 
order to impede uncontrolled movement that may detrimentally affect the healing process. The 
aforementioned method provides reproducible mechanical conditions, while minimizing the 
interference of the implant with surrounding soft tissues and allowing the biological response to 
fractures [16]. Conversely, intramedullary nails provide little stability and poorly defined 
biomechanical conditions for the fracture site, resulting in a less reproducible model [17]. 
Another important characteristic of a reliable animal model of septic non-union concerns the 
features of the fracture gap. In order to create reproducible fracture gaps, we performed an 
osteotomy with a circular saw, since it has been demonstrated that bone healing in this case is 
comparable to that of normal fractures [18]. Thus, the reproducibility of this model and the 
comparability of the results are expected to be high.  
Moreover, to understand the role of bacteria in non-union development, it is important to avoid the 
generation of critical size bone defects. A critical size defect is defined as a bone defect that will 
not heal completely over the natural lifetime of an animal [19]. Hence, there is the need to develop 
non-unions through the establishment of an infection, rather than through a critical size bone defect.  
Once the stabilization and the fracture methods were assessed, the other crucial decision was the 
choice of the bacterial species and strain involved in the development of this model. According to 
data reported by the National Health Care Safety Network, coagulase-negative staphylococci 
(CoNS) are the most frequent cause of implant- or surgery-associated nosocomial infections in the 
United State of America, and among them, the most frequently isolated CoNS is Staphylococcus 
epidermidis [20, 21]. Indeed, S. epidermidis has recently emerged as a common cause of 
nosocomial infections associated with medical devices (e.g., catheters, pacemakers, metal implants, 
etc.). Interestingly, S. epidermidis was rarely pathogenic before the advent of modern medicine and 
before the massive use of indwelling devices, but now it is recognized as an important human 
pathogen [22]. This is mainly due to its presence on healthy human skin as a commensal bacterium: 
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the skin of healthy people is normally colonized by 10-24 S. epidermidis strains at any time, notably 
increasing the risk of contamination during surgery [23].  
S. epidermidis is commonly classified as low virulence pathogen compared to S. aureus since it 
does not encode many pathogenicity islands. Its major virulent propriety is the ability to form 
biofilm on implants enabling bacteria to live in a protected environment, without being affected by 
the host immune system. S. epidermidis contaminations often result in low-grade infections in 
which patients complain about persistent pain and/or functional impairment, with mixed positive 
and negative markers of infection and inflammation [9, 24]. 
To recreate a setting as closer as possible to clinics, a clinical methicillin-resistant S. epidermidis 
isolate (MRSE) was employed due to its ability to contaminate implants. In this regard, the most 
challenging aspect in designing an animal model with clinical isolates is to determine the bacterial 
concentration able to induce the infection with respect to the virulence of the inoculated pathogen 
[9]. In the first experimental phase of this project, we were able to establish three clinically different 
tools to study prophylactic and therapeutic strategies. In particular, we were able to demonstrate 
that the use of a low S. epidermidis concentration (103 CFU/inoculum) established a subclinical 
onset characterized by an inconsistent grade of non-union development without any signs or 
symptoms of infection. Animals in this group were characterized by a high variability in the 
development of the septic non-union because sometimes the host immune response was able to 
spontaneously eradicate the infection (33% of the animals). However, this model can be an 
important tool to analyze the signs of subclinical events in terms of pathogenesis and host response. 
Conversely, the injection of a high amount of S. epidermidis (108 CFU/inoculum) systematically 
resulted in the impairment of fracture healing caused by rapid biofilm formation on the implant 
surface. All the animals in this group showed signs of a chronic condition in which biofilm played 
a crucial part in camouflaging bacteria from the host immune system. This model of chronic non-
union can be used to investigate methods to detect or disrupt mature biofilm in vivo. 
The reduction of the bacterial load to 105 CFU/inoculum resulted in a sub-acute host response 
characterized by the presence of free cocci in the fracture site. The signs of osteomyelitis were 
severe, with vascular and bone damage, that affected the stability of the fracture, impairing the 
healing process. Sub-acute events can be reasonably controlled by preventive antimicrobial 
treatment, since bacteria are poorly embedded in a weak and immature extracellular matrix. 
The achievements obtained in the first part of the project made it possible to evaluate different non-
union preventive strategies (Chapter 2). Clinically, systemic pharmacological treatments are 
routinely used to prevent implant-related infections; despite this, localized strategies have several 
advantages including being able to deliver antibacterial agents to the injured site thus requiring 
lower drug dosages, and reducing systemic side effects [25]. When dealing with fracture 
stabilization, the local application of antibacterial coatings may be a promising approach to prevent 
the establishment of infections. However, the development of new antibacterial coatings for this 
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purpose appears extremely challenging [26]. The coating itself should not interfere with the implant 
osseointegration, while actively preventing bacterial adhesion during its half-life [27]. Moreover, 
when enriched with antibiotics, the half-life of the coating should be brief enough to prevent both 
biofilm formation and the development of antibiotic resistance [26]. In our experimental setting, 
we exploited the biodegradability and osteoinductive features of a new hydrogel enriched with 
vancomycin, used as a coating, to test its antimicrobial properties. In particular, we compared its 
use to the systemic injection of vancomycin, as the gold standard in the treatment of septic non-
unions characterized by the presence of methicillin-resistant bacteria. Both the systemic injection 
and the local delivery of vancomycin by means of the hydrogel resulted in a good response in terms 
of bone healing and absence of osteomyelitis, suggesting the synergistic use of these two treatments 
as an effective strategy to prevent the establishment of septic non-unions [28]. Along with this 
possible strategy, this study aimed also at testing the feasibility of the bone marrow mesenchymal 
stem cells BMSCs cell therapy for this purpose.  
In the last few years, cell-based therapy has achieved impressive results in the restoration of tissue 
function, as well as in the treatment of non-unions [29-31]. BMSCs has been used as an accessible 
source of progenitor cells able to differentiate in mesenchymal tissue and as a safe source, due to 
the lack of major histocompatibility complex II (MHC II) which permits the allogeneic transplant 
of these cells [32]. This important characteristic made it possible to study the role of allogeneic 
BMSCs in bone defect and non-union fracture in a clinical trial (ClinicalTrials.gov 
#NCT02307435). Furthermore, BMSCs immunomodulatory and antimicrobial features have been 
recently demonstrated [33-36]. Thus, we applied our rat model of sub-acute septic non-union to 
study the immunomodulatory effects of allogeneic BMSCs by measuring the systemic level of 
inflammatory cytokines and their role in the prevention of infection and bone healing. The detection 
of a set of mediators correlated with the septic non-union inflammatory process may promote a 
better understanding of the physiopathology of bone healing while offering new diagnostic 
biomarkers. Unfortunately, there were some limitations in our study. The intravenous injection of 
BMSCs caused the death of 50% of the animals due to the “pulmonary first-pass theory”, as 
supported by the histopathological analyses. This outcome was unpredicted, since the amount of 
injected BMSCs was concordant with the dose used in other preclinical and clinical studies 
presented in the literature [37, 38, ClinicalTrials.gov #NCT02307435] and it may be related to cell 
adhesion or to the activation of the coagulation pathway [38, 39]. A possible approach to reduce 
the risk of pulmonary embolism could be the use of vasodilators or anticoagulants in conjunction 
with the systemic injection of BMSCs, or again, the use of a syringe pump to slowly perfuse the 
solution containing the cells. However, further manipulation of BMSCs might negatively influence 
cell viability and function once transplanted in vivo [40]. 
Due to this drawback, data obtained by the systemic use of BMSCs are not able to support definitive 
conclusions and should be considered as a preliminary study, given the reduced sample size of the 
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group. However, it is necessary to identify an effective, time-convenient and safe administration 
route for BMSC transplantation, taking into consideration the risks related to the use of BMSCs in 
regenerative medicine (e.g., dimensions, proliferation capability, differentiation status, etc.). More 
importantly, it is fundamental to state in scientific publications the occurrence of animal death 
following a treatment in order to be aware of the risks connected with the proposed procedure. 
Another limitation of the study is linked to the analysis of the serum cytokine, which is strictly 
correlated to the patients’ health and infection status. Indeed, stress condition and the experimental 
time points of blood withdraws and analyses may have a crucial part in the detection of cytokine 
levels, eventually introducing biases in their analysis [41]. Hence, there is the need to identify new 
and stable markers of infections in order to target bacterial biofilm determinants, intensifying 
molecular research focused on biofilm-mediated infections. 
The aim of the last part of my Ph.D. project was to define future diagnostic biomarkers to detect 
latent implant-related infections and new therapeutic targets, using a comparative proteomic study 
to analyze mature staphylococcal biofilms.  
The investigation of the interaction between host and microorganisms is certainly difficult due to 
the enormous number of variables implicated. Therefore, the need to thoroughly understand the 
mechanisms related to biofilm-mediated infections and their pathogenesis encouraged the scientific 
community to pour over the causes of bone healing impairment, starting from the main cause: 
biofilm producing bacteria.  
Through the comparison of genomes of various types of bacteria, it is possible to identify the key 
factors responsible for different bacterial virulence, as well as factors regulating biofilm production 
[22]. The success of S. epidermidis as a pathogen relies on its ability to adhere to foreign body 
surfaces and to form biofilm, causing sub-acute and chronic infections [42]. The advent of the post-
genomic era rapidly advanced the understanding of microorganisms’ biology. Through proteomic 
analyses, it is now possible to assay the expression of target genes and evaluate their modulation in 
accordance with different growing conditions. Sorting individual proteins from heterogeneous 
samples can be performed by an initial separation according to their isoelectric point followed by a 
second-dimension separation based on their molecular weight. The resulting two-dimensional map 
of proteins provides a wide-ranging view of proteins expressed under certain conditions, showing 
variations in the level of expression, and showing either the presence of isoforms or post-
translational modifications. However, protein identification requires the availability of genomic 
information in public databases, such as functional annotation of sequenced genes. For this reason, 
in order to appropriately identify changes in the proteomic profile of the clinical isolates, the whole 
genome of S. epidermidis GOI1153754-03-14 used in our rat model of septic non-union, was 
sequenced through next generation sequences analysis (Chapter 3). The deposition of its genomic 
sequence in the ENA public database not only is important for the proteomic analysis of the 
specimen, but also will enable a deeper insight into the mechanisms of orthopedic infections. 
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Profiling the gene expression pattern of biofilm producing bacteria thorough omics science is 
important to decipher the genetic basis of biofilm formation. Moreover, the protection conferred by 
biofilm permits bacteria to quietly survive within the host for long periods of time without being 
detected by the immune system. In this particular scenario, defining therapeutic targets or 
diagnostic biomarkers is mandatory to detect latent or chronic infections mediated by low virulence, 
biofilm forming bacteria, such as S. epidermidis [43].  
With the aim to define markers expressed by a mature staphylococcal biofilm on metallic implants, 
the proteome of S. epidermidis GOI1153754-03-14 was compared to that of S. epidermidis ATCC 
35984 to evaluate the induction or repression of individual proteins as the result of sessile or 
planktonic cultures (Chapter 4). The analysis of the proteins expressed under these different culture 
conditions after 72 hours of growth can provide information regarding both the mechanisms behind 
biofilm steady state and the differences of the two tested bacterial strains. To recreate a mature 
biofilm in vitro, S. epidermidis was cultured on sandblasted titanium disks for 72 hours, according 
to an experimental time point set in a previous study [44]. Indeed, Drago and colleagues [44] 
demonstrated through confocal microscopic analysis that bacteria are able to establish a mature 
biofilm on titanium disks after 72 hours of culture. However, data obtained in our study revealed 
that many changes in protein expression in both S. epidermidis strains occurred when planktonically 
cultured. In particular, the analysis of the proteins expressed by planktonic bacteria after 72 hours 
revealed some unexpected results linked to bacterial stress. A high cell density in a close 
environment without renewed nutrients inevitably results in an alteration of the physiological cell 
balance; harsh conditions such as nutrient deprivation, pH decrease, exposure to oxygen and 
nitrogen species predictably lead to global stress responses [45]. The chosen experimental time 
point represents a limit of this study, but also an important clue for future analyses. Indeed, in order 
to compare the features of mature biofilm, there is a need to study gene expression of bacteria at 
different experimental time points. For this reason, proteomic analysis of S. epidermidis 
GOI1153754-03-14 and ATCC35984 at different time points may overcome these limitations due 
to cell density while allowing the comparison of their proteomes at the same experimental time 
points.  
The study of regulatory mechanisms of biofilm-mediated infections may encourage the 
development of innovative therapeutic strategies to discourage bacterial colonization of medical 
devices at the molecular level. However, the presence of biofilm makes the diagnosis of infections 
and the subsequent selection of the apposite treatment particularly challenging [44, 46]. Biofilms 
may slow the metabolism of bacteria, while prolonging their survival inside the infected host, 
leading to chronic infections and favoring also the development of antibiotic resistances [47]. 
Although many efforts have been made to improve the sensitivity of tests for the diagnosis of 
implant-related infections, a microbiological gold standard has not yet been established. 
Consequently, guidelines have been discussed and proposed at national and international meetings 
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[48-50]. The technological progression of the field might be achieved through the standardization 
of the protocols in the scientific community. Hence, to promote the advancement of knowledge of 
the human proteome, in 2010, the Human Proteome Organization (HUPO) and the Human 
Proteome Project (HPP) were founded [51]. Through the alliance of independent groups of 
scientists whose research is focused on specific diseases or molecular processes, it will be possible 
to provide standardized methods and resources for mass spectrometry and to facilitate accessibility 
of these resources to the broader life science research and clinical communities. In the near future, 
the standardization of protocols along with the study of many different biofilm-forming bacterial 
species might make it possible to identify chronic infections thereby defining the antibiotic 
susceptibility profile of the bacteria involved and subsequently the best therapeutic strategy by the 
analysis of sera of patients. 
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